

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1276	((synthesized or synthetic or artificial or optimal or optimized or optimize) adj (promoter)) and (spacer or (spacer adj region) or intron)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/06 09:05
L2	814	L1 and @ad<"20030218"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/06 09:20
L3	460	L2 and (((genetic adj immunization) or (genetic adj (vaccine or vaccination)) or (DNA-based adj (vaccine or vaccination)) or (DNA adj (vaccine or vaccination)) or (gene adj therapy)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	SAME	ON	2006/04/06 09:07
L4	6	L3 and ((TFIIB or (transcription adj factor adj IIB)) and (Tata adj box))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/06 09:11
L5	6	L4 and ((enhancer))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/06 08:18
L13	2	"20040171573"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/06 09:00
L14	506541	(spacer or (spacer adj region))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/06 09:01
L15	394	((synthesized or synthetic or artificial or optimal or optimized or optimize) adj (promoter)) and (spacer or (spacer adj region))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/06 09:05
L16	238	L15 and @ad<"20030218"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/06 09:06

EAST Search History

L17	3	L16 and ((TFIIB or (transcription adj factor adj IIB)) and (Tata adj box))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/06 09:06
L18	2	L17 and (((genetic adj immunization) or (genetic adj (vaccine or vaccination)) or (DNA-based adj (vaccine or vaccination)) or (DNA adj (vaccine or vaccination)) or (gene adj therapy)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	SAME	ON	2006/04/06 09:07
L19	80	promoter and ((TFIIB or (transcription adj factor adj IIB)) and (Tata adj box) and (initiation or initiat\$\$) and (upstream with (element or site or region)) and (downstream with (element or site or region)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/06 09:41
L20	57	L19 and @ad<"20030218"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/06 09:42
L21	16	promoter and ((TFIIB or (transcription adj factor adj IIB)) and (Tata adj box) and (initiation or initiat\$\$) and (upstream with (element or site or region)) and ((downstream adj promoter) with (element or site or region)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/06 10:55
L22	25	promoter and ((TFIIB or (transcription adj factor adj IIB)) and (Tata adj box) and (initiation or initiat\$\$) and (upstream with (element or site or region)) and ((downstream adj promoter)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/06 09:42
L23	17	L22 and @ad<"20030218"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/06 09:42
L24	7	promoter and (((TFIIB or (transcription adj factor adj IIB))with (element or site or region))and (Tata adj box) and (initiation or initiat\$\$) and (upstream with (element or site or region)) and ((downstream adj promoter) with (element or site or region)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/06 10:56

EAST Search History

L25	1	L24 and ((((((interferon adj regulatory adj factor) or irf) adj binding adj (element or site or region)) or (((interferon adj regulatory adj factor) or irf) adj (element or site or region))) or IRF or IRF-E or IRF-1 or IRF1 or IRF2 or IRF-2 or (interferon adj regulatory adj factor))) and (SP-1 or SP1))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/06 11:01
L26	2	L24 and ((((((interferon adj regulatory adj factor) or irf) adj binding adj (element or site or region)) or (((interferon adj regulatory adj factor) or irf) adj (element or site or region))) or IRF or IRF-E or IRF-1 or IRF1 or IRF2 or IRF-2 or (interferon adj regulatory adj factor))) or (SP-1 or SP1))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/06 11:02
L27	2	L24 and ((sp1 or sp-1 or irf or IRF-1 or IRF-e or IRF-2 or (interferon adj regulatory adj factor) or (((interferon adj regulatory adj factor) or irf) adj binding adj (element or site or region)) or (((interferon adj regulatory adj factor) or irf) adj (element or site or region))) or IRF-E or IRF-1 or IRF-2) or cbp or (creb adj binding adj protein) or (Cat adj binding adj protein) or AP-1 or AP1 or (activation adj protein) or C-jun or NFkB or ("NF.kappa.B") or CREB/ATF or NF1 or NF-1))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/06 11:03
S1	2	"20040171573"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 12:00
S2	2	"4683202".pn.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 13:19
S3	2	"5928906".pn.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 17:28

EAST Search History

S4	2	"6410210".pn.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 13:59
S5	1796	((synthesized or synthetic) adj (promoter or enhancer))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 17:32
S6	979	((((synthesized or synthetic) adj (promoter or enhancer))) and optimiz\$\$	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 14:03
S7	69	((((synthesized or synthetic) adj (promoter or enhancer))) same optimiz\$\$	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 14:47
S8	34	((((synthesized or synthetic) adj (promoter or enhancer))) with optimiz\$\$	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 17:49
S9	5967	(genetic adj immunization) or (genetic adj (vaccine or vaccination)) or (DNA-based adj (vaccine or vaccination)) or (DNA adj (vaccine or vaccination))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 14:05
S10	3	S8 and ((genetic adj immunization) or (genetic adj (vaccine or vaccination)) or (DNA-based adj (vaccine or vaccination)) or (DNA adj (vaccine or vaccination)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 14:11
S11	15	S7 and ((genetic adj immunization) or (genetic adj (vaccine or vaccination)) or (DNA-based adj (vaccine or vaccination)) or (DNA adj (vaccine or vaccination)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 14:08
S12	6	S11 and @ad<"20030218"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 14:12

EAST Search History

S13	2	S8 same ((genetic adj immunization) or (genetic adj (vaccine or vaccination)) or (DNA-based adj (vaccine or vaccination)) or (DNA adj (vaccine or vaccination)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 14:10
S14	11	S8 and ((genetic adj immunization) or (genetic adj (vaccine or vaccination)) or (DNA-based adj (vaccine or vaccination)) or (DNA adj (vaccine or vaccination)) or (gene adj therap\$\$))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 17:33
S15	7	S14 and @ad<"20030218"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 17:33
S16	1	(TATA adj box) and (TFIIB adj binding adj element) and (initiator or inr) and (downstream adj promoter adj element) and ((upstream adj promoter adj element) or (IRF adj binding adj element))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 15:30
S17	1	S7 and ((TATA adj box) and (TFIIB adj binding adj element) and (initiator or inr) and (downstream adj promoter adj element) and ((upstream adj promoter adj element) or (IRF adj binding adj element)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 14:30
S18	1	(TATA adj box) and (TFIIB adj binding adj element) and (initiator or inr) and (downstream adj promoter adj element) and ((upstream adj promoter adj element) or ((IRF adj binding adj element) or (interferon adj regulatory adj factor adj binding adj factor) or (IRF adj binding adj element) or (.alpha.-interferon" adj regulatory adj factor adj binding adj element)) or (((IRF adj binding adj element) or (interferon adj regulatory adj factor adj binding adj factor) or (IRF adj binding adj element)) and (SP1 adj binding adj element)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 14:34

EAST Search History

S19	686	((upstream adj promoter adj element) or ((IRF adj binding adj element) or (interferon adj regulatory adj factor adj binding adj factor) or (IRF adj binding adj element) or ("alpha.-interferon" adj regulatory adj factor adj binding adj element)) or (((IRF adj binding adj element) or (interferon adj regulatory adj factor adj binding adj factor) or (IRF adj binding adj element)) and (SP1 adj binding adj element)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 14:50
S20	1	S19 and ((TATA adj box) and (TFIIB adj binding adj element) and (initiator or inr) and (downstream adj promoter adj element))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 14:51
S21	685	(upstream adj promoter adj element)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 14:47
S22	264	((synthesized or synthetic) adj (promoter or enhancer)) and (upstream adj promoter adj element)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 14:47
S23	6	(((((synthesized or synthetic) adj (promoter or enhancer))) same optimiz\$\$) and (upstream adj promoter adj element)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 14:48
S24	1	S23 and @ad<"20030218"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 14:48
S25	1	S8 and (((upstream adj promoter adj element) or ((IRF adj binding adj element) or (interferon adj regulatory adj factor adj binding adj factor) or (IRF adj binding adj element) or ("alpha.-interferon" adj regulatory adj factor adj binding adj element)) or (((IRF adj binding adj element) or (interferon adj regulatory adj factor adj binding adj factor) or (IRF adj binding adj element)) and (SP1 adj binding adj element))))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 14:52

EAST Search History

S26	265	S5 and (((upstream adj promoter adj element) or ((IRF adj binding adj element) or (interferon adj regulatory adj factor adj binding adj factor) or (IRF adj binding adj element) or ("alpha.-interferon" adj regulatory adj factor adj binding adj element)) or (((IRF adj binding adj element) or (interferon adj regulatory adj factor adj binding adj factor) or (IRF adj binding adj element)) and (SP1 adj binding adj element))))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 14:51
S27	1	S26 and ((TATA adj box) and (TFIIB adj binding adj element) and (initiator or inr) and (downstream adj promoter adj element))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 14:51
S28	1	S8 and ((((IRF adj binding adj element) or (interferon adj regulatory adj factor adj binding adj factor) or (IRF adj binding adj element)) and (SP1 adj binding adj element))))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 14:52
S29	1	((((IRF adj binding adj element) or (interferon adj regulatory adj factor adj binding adj factor) or (IRF adj binding adj element)) and (SP1 adj binding adj element))))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 14:54
S30	1	((IRF adj binding adj (element or site)) or (interferon adj regulatory adj factor adj binding adj (element or site)) or (IRF adj binding adj (element or site)) or (interferon adj regulatory adj factor-1 adj binding adj (element or site))) and (SP1 adj binding adj (element or site)) and (CBP adj binding adj (element or site)) or (Cat adj binding adj protein adj binding adj (element or site)) and ("NF.kappa.B" adj binding adj (element or site)) and (AP1 adj binding adj (element or site)) or (activation adj protein adj binding adj (element or site)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 15:05
S31	1	(TATA adj box) and (TFIIB adj binding adj (element or site)) and (initiator or inr) and (downstream adj promoter adj (element or site)) and ((upstream adj promoter adj (element or site)) or (IRF adj binding adj (element or site)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 15:28

EAST Search History

S32	0	(TATA adj box) and ((TFIIB adj binding adj element) or (TFIIB adj element) or (TFIIB adj binding adj site)) and (initiator or inr) and ((downstream adj promoter adj element) or (downstream adj element) or (downstream adj promoter adj site)) and ((upstream adj promoter adj element) or (upstream adj element) or (upstream adj promoter adj site))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 15:33
S33	0	(TATA adj box) and ((TFIIB adj binding adj element) or (TFIIB adj site) or (TFIIB adj element) or (TFIIB adj binding adj site)) and (initiator or inr) and ((downstream adj promoter adj element) or (downstream adj element) or (downstream adj site) or (downstream adj promoter adj site)) and ((upstream adj promoter adj element) or (upstream adj element) or (upstream adj site) or (upstream adj promoter adj site))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 15:34
S34	0	((TATA adj box) or (TATA)) and ((TFIIB adj binding adj element) or (TFIIB adj site) or (TFIIB adj element) or (TFIIB adj binding adj site)) and (initiator or inr) and ((downstream adj promoter adj element) or (downstream adj element) or (downstream adj site) or (downstream adj promoter adj site)) and ((upstream adj promoter adj element) or (upstream adj element) or (upstream adj site) or (upstream adj promoter adj site))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 15:39
S35	0	((TFIIB adj binding adj element) or (TFIIB adj site) or (TFIIB adj element) or (TFIIB adj binding adj site)) and (initiator or inr) and ((downstream adj promoter adj element) or (downstream adj element) or (downstream adj site) or (downstream adj promoter adj site)) and ((upstream adj promoter adj element) or (upstream adj element) or (upstream adj site) or (upstream adj promoter adj site))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 15:36

EAST Search History

S36	39	((initiator or inr) and ((downstream adj promoter adj element) or (downstream adj element) or (downstream adj site) or (downstream adj promoter adj site)) and ((upstream adj promoter adj element) or (upstream adj element) or (upstream adj site) or (upstream adj promoter adj site)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 15:37
S37	0	((TATA adj box) or (TATA)) and ((TFIIB adj binding adj element) or (TFIIB adj site) or (TFIIB adj element) or (TFIIB adj binding adj site)) and ((downstream adj promoter adj element) or (downstream adj element) or (downstream adj site) or (downstream adj promoter adj site)) and ((upstream adj promoter adj element) or (upstream adj element) or (upstream adj site) or (upstream adj promoter adj site)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 15:36
S38	598	((downstream adj promoter adj element) or (downstream adj element) or (downstream adj site) or (downstream adj promoter adj site)) and ((upstream adj promoter adj element) or (upstream adj element) or (upstream adj site) or (upstream adj promoter adj site)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 15:37
S39	3724	((upstream adj promoter adj element) or (upstream adj element) or (upstream adj site) or (upstream adj promoter adj site)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 15:37
S40	16	((TATA adj box) or (TATA)) and ((initiator or inr) and ((downstream adj promoter adj element) or (downstream adj element) or (downstream adj site) or (downstream adj promoter adj site)) and ((upstream adj promoter adj element) or (upstream adj element) or (upstream adj site) or (upstream adj promoter adj site)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 15:38

EAST Search History

S41	0	((TATA adj box) or (TATA)) and ((TFIIB adj binding adj element) or (TFIIB adj site) or (TFIIB adj element) or (TFIIB adj binding adj site)) and ((downstream adj promoter adj element) or (downstream adj element) or (downstream adj site) or (downstream adj promoter adj site)) and ((upstream adj promoter adj element) or (upstream adj element) or (upstream adj site) or (upstream adj promoter adj site))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 15:39
S42	0	((TATA adj box) or (TATA)) and ((TFIIB adj binding adj element) or (TFIIB adj site) or (TFIIB adj element) or (TFIIB adj binding adj site)) and (initiator or inr) and ((upstream adj promoter adj element) or (upstream adj element) or (upstream adj site) or (upstream adj promoter adj site))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 15:39
S43	2	((TATA adj box) or (TATA)) and ((TFIIB adj binding adj element) or (TFIIB adj site) or (TFIIB adj element) or (TFIIB adj binding adj site)) and (initiator or inr) and ((downstream adj promoter adj element) or (downstream adj element) or (downstream adj site) or (downstream adj promoter adj site))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 15:39
S44	2	"6706688".pn.	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 17:28
S45	16	((synthesized or synthetic or artificial) adj (promoter near enhancer))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 17:32
S46	11	S45 and @ad<"20030218"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 17:53
S47	4	S46 and ((genetic adj immunization) or (genetic adj (vaccine or vaccination)) or (DNA-based adj (vaccine or vaccination)) or (DNA adj (vaccine or vaccination)) or (gene adj therap\$))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 17:36

EAST Search History

S48	2	S45 same (((genetic adj immunization) or (genetic adj (vaccine or vaccination)) or (DNA-based adj (vaccine or vaccination)) or (DNA adj (vaccine or vaccination)) or (gene adj therap\$\$)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	SAME	ON	2006/04/05 09:03
S49	2	((synthesized or synthetic or artificial) adj (promoter near enhancer)) with optimiz\$\$	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 17:55
S50	3	((synthesized or synthetic or artificial) adj (promoter near enhancer)) same optimiz\$\$	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 17:51
S51	9	((synthesized or synthetic or artificial) adj (promoter near enhancer)) and optimiz\$\$	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 17:51
S52	2	(((synthesized or synthetic or artificial) adj (promoter near enhancer)) and optimiz\$\$) same (((genetic adj immunization) or (genetic adj (vaccine or vaccination)) or (DNA-based adj (vaccine or vaccination)) or (DNA adj (vaccine or vaccination)) or (gene adj therap\$\$)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	SAME	ON	2006/04/04 17:52
S53	0	(((synthesized or synthetic or artificial) adj (promoter with enhancer)) and optimiz\$\$) same (((genetic adj immunization) or (genetic adj (vaccine or vaccination)) or (DNA-based adj (vaccine or vaccination)) or (DNA adj (vaccine or vaccination)) or (gene adj therap\$\$)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	SAME	ON	2006/04/04 17:52
S54	0	(((synthesized or synthetic or artificial) adj (promoter same enhancer)) and optimiz\$\$) same (((genetic adj immunization) or (genetic adj (vaccine or vaccination)) or (DNA-based adj (vaccine or vaccination)) or (DNA adj (vaccine or vaccination)) or (gene adj therap\$\$)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	SAME	ON	2006/04/04 17:52

EAST Search History

S55	0	((((synthesized or synthetic or artificial) adj (promoter and enhancer)) and optimiz\$\$) same (((genetic adj immunization) or (genetic adj (vaccine or vaccination)) or (DNA-based adj (vaccine or vaccination)) or (DNA adj (vaccine or vaccination)) or (gene adj therap\$\$)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	SAME	ON	2006/04/04 17:53
S56	0	((((synthesized or synthetic or artificial) adj (promoter adj enhancer)) and optimiz\$\$) same (((genetic adj immunization) or (genetic adj (vaccine or vaccination)) or (DNA-based adj (vaccine or vaccination)) or (DNA adj (vaccine or vaccination)) or (gene adj therap\$\$)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	SAME	ON	2006/04/04 17:53
S57	2	((((synthesized or synthetic or artificial) adj (promoter adj enhancer)) and optimiz\$\$) same (((genetic adj immunization) or (genetic adj (vaccine or vaccination)) or (DNA-based adj (vaccine or vaccination)) or (DNA adj (vaccine or vaccination)) or (gene adj therap\$\$)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	SAME	ON	2006/04/04 17:53
S58	5	((((synthesized or synthetic or artificial) adj (promoter adj enhancer)) and optimiz\$\$) and (((genetic adj immunization) or (genetic adj (vaccine or vaccination)) or (DNA-based adj (vaccine or vaccination)) or (DNA adj (vaccine or vaccination)) or (gene adj therap\$\$)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	SAME	ON	2006/04/04 17:53
S59	2	S58 and @ad<"20030218"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 17:56
S60	2	((synthesized or synthetic or artificial) near (promoter near enhancer)) with optimiz\$\$	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 17:55
S61	0	((synthesized or synthetic or artificial) near (promoter with enhancer)) with optimiz\$\$	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 17:55

EAST Search History

S62	0	((synthesized or synthetic or artificial) near (promoter same enhancer)) with optimiz\$\$	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 17:55
S63	8	((synthesized or synthetic or artificial) with (promoter same enhancer)) with optimiz\$\$	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 17:55
S64	5	S63 and @ad<"20030218"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/04 17:56
S65	2	S64 and (((genetic adj immunization) or (genetic adj (vaccine or vaccination)) or (DNA-based adj (vaccine or vaccination)) or (DNA adj (vaccine or vaccination)) or (gene adj therap\$))))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	SAME	ON	2006/04/04 17:56
S66	16	irf adj binding adj (element or site or region)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 08:34
S67	19	(irf adj binding adj (element or site or region)) or (irf adj (element or site or region))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 08:48
S68	11	S67 and @ad<"20030218"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 08:54
S69	0	S68 and ((synthesized or synthetic or artificial) adj (promoter near enhancer))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 08:51
S70	0	S68 and ((synthesized or synthetic or artificial) adj (promoter and enhancer))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 08:39

EAST Search History

S71	0	S68 and ((synthesized or synthetic or artificial) adj (promoter))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 08:39
S72	16	((((interferon adj regulatory adj factor) or irf) adj binding adj (element or site or region))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 08:49
S73	22	((((interferon adj regulatory adj factor) or irf) adj binding adj (element or site or region)) or (((interferon adj regulatory adj factor) or irf) adj (element or site or region)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 14:11
S74	1	S73 and ((synthesized or synthetic or artificial) adj (promoter))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 08:57
S75	1	S73 and ((synthesized or synthetic or artificial or optimiz\$\$) adj (promoter))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 08:52
S76	12	S73 and @ad<"20030218"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 11:14
S77	2248	((synthesized or synthetic or artificial or optimal or optimized or optimize) adj (promoter))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 18:19
S78	9	((synthesized or synthetic or artificial or optimal or optimized or optimize) adj (promoter and enhancer))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 13:55
S79	4	S78 and (((genetic adj immunization) or (genetic adj (vaccine or vaccination)) or (DNA-based adj (vaccine or vaccination)) or (DNA adj (vaccine or vaccination)) or (gene adj therapy)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	SAME	ON	2006/04/05 11:14

EAST Search History

S80	1	((optimal or optimized or optimize) adj (promoter and enhancer))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 11:13
S81	116	((optimal or optimized or optimize) adj (promoter))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 11:13
S82	10	((optimal or optimized or optimize) adj (enhancer))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 11:14
S83	58	S81 and (((genetic adj immunization) or (genetic adj (vaccine or vaccination)) or (DNA-based adj (vaccine or vaccination)) or (DNA adj (vaccine or vaccination)) or (gene adj therapy)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	SAME	ON	2006/04/05 17:18
S84	3	S82 and (((genetic adj immunization) or (genetic adj (vaccine or vaccination)) or (DNA-based adj (vaccine or vaccination)) or (DNA adj (vaccine or vaccination)) or (gene adj therapy)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	SAME	ON	2006/04/05 11:14
S85	38	S83 and @ad<"20030218"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:18
S86	3	S84 and @ad<"20030218"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 13:54
S87	38	S85 and ((synthesized or synthetic or artificial or optimal or optimized or optimize) near (promoter))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 13:55
S88	7	S85 and ((synthesized or synthetic or artificial) near (promoter))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 14:05

EAST Search History

S89	24	S85 and ((synthesized or synthetic or artificial) with (promoter))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 13:56
S90	0	S89 and ((synthesized or synthetic or artificial) near (enhancer))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 14:06
S91	22	S89 and ((enhancer))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:18
S92	0	S91 and (((((interferon adj regulatory adj factor) or irf) adj binding adj (element or site or region)) or (((((interferon adj regulatory adj factor) or irf) adj (element or site or region))))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 14:12
S93	0	S91 and (((((interferon adj regulatory adj factor) or irf) adj binding adj (element or site or region)) or (((((interferon adj regulatory adj factor) or irf) adj (element or site or region))) or IRF-E or IRF-1 or IRF-2)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 14:13
S94	0	S86 and (((((interferon adj regulatory adj factor) or irf) adj binding adj (element or site or region)) or (((((interferon adj regulatory adj factor) or irf) adj (element or site or region))) or IRF-E or IRF-1 or IRF-2)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:21
S95	7	S91 and (sp1 or sp-1 or irf or IRF-1 or IRF-e or IRF-2 or (interferon adj regulatory adj factor) or cbp or (Cat adj binding adj protein) or AP-1 or AP1 or (activation adj protein) or C-jun or NFkB or ("NF.kappa.B") or CREB/ATF or NF1 or NF-1)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 18:02
S96	3	S84 and (sp1 or sp-1 or irf or IRF-1 or IRF-e or IRF-2 or (interferon adj regulatory adj factor) or cbp or (Cat adj binding adj protein) or AP-1 or AP1 or (activation adj protein) or C-jun or NFkB or ("NF.kappa.B") or CREB/ATF or NF1 or NF-1)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:09

EAST Search History

S97	84	(Tata adj box) and (initiation) and (upstream adj regulatory) and (((downstream adj regulatory) or (downstream adj promoter adj (element or site or region)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:30
S98	6	S97 and ((synthesized or synthetic or artificial or optimal or optimized or optimize) adj (promoter))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:37
S99	0	S97 and ((synthesized or synthetic or artificial or optimal or optimized or optimize) adj (enhancer))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:18
S100	6	S98 and ((enhancer))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:38
S101	6	S100 and (((genetic adj immunization) or (genetic adj (vaccine or vaccination)) or (DNA-based adj (vaccine or vaccination)) or (DNA adj (vaccine or vaccination)) or (gene adj therapy)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	SAME	ON	2006/04/05 17:38
S102	6	S101 and @ad<"20030218"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:39
S103	0	S102 and (((((interferon adj regulatory adj factor) or irf) adj binding adj (element or site or region)) or (((((interferon adj regulatory adj factor) or irf) adj (element or site or region))) or IRF-E or IRF-1 or IRF-2)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:22
S104	0	S102 and (((((interferon adj regulatory adj factor) or irf) adj binding adj (element or site or region)) or (((((interferon adj regulatory adj factor) or irf) adj (element or site or region))) or IRF or IRF-E or IRF-1 or IRF-2)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:22

EAST Search History

S10 5	0	S102 and (((interferon adj regulatory adj factor) or irf) adj binding adj (element or site or region)) or (((interferon adj regulatory adj factor) or irf) adj (element or site or region))) or IRF or IRF-E or IRF-1 or IRF-2 or (interferon adj regulatory adj factor))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:23
S10 6	0	S102 and (((interferon adj regulatory adj factor) or irf) adj binding adj (element or site or region)) or (((interferon adj regulatory adj factor) or irf) adj (element or site or region))) or IRF or IRF-E or IRF-1 or IRF1 or IRF2 or IRF-2 or (interferon adj regulatory adj factor))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:48
S10 7	0	(Tata adj box) and (initiation) and TFIIB and (upstream adj regulatory) and ((downstream adj regulatory) or (downstream adj promoter adj (element or site or region)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:32
S10 8	0	(Tata adj box) and (initiation) and (TFIIB or (transcription adj factor adj IIB)) and (upstream adj regulatory) and ((downstream adj regulatory) or (downstream adj promoter adj (element or site or region)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:33
S10 9	391	(TFIIB or (transcription adj factor adj IIB))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:33
S11 0	139	(TFIIB or (transcription adj factor adj IIB)) and (Tata adj box)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:51
S11 1	133	(TFIIB or (transcription adj factor adj IIB)) and (Tata adj box) and (initiation or initiation)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:52
S11 2	18	(TFIIB or (transcription adj factor adj IIB)) and (Tata adj box) and (initiation or initiation) and ((upstream with (binding adj element)) or (upstream with (regulatory adj element)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:35

EAST Search History

S11 3	54	(TFIIB or (transcription adj factor adj IIB)) and (Tata adj box) and (initiation or initiation) and ((upstream with (binding adj element)) or (upstream with (regulatory adj element)) or (upstream with enhancer))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:52
S11 4	57	(TFIIB or (transcription adj factor adj IIB)) and (Tata adj box) and (initiation or initiation) and ((upstream with (binding adj element)) or (upstream with (regulatory adj element)) or (upstream with enhancer) or (upstream with promoter)) and ((downstream with (binding adj element)) or (downstream with (regulatory adj element)) or (downstream with enhancer) or (downstream with promoter))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:53
S11 5	10	S114 and ((synthesized or synthetic or artificial or optimal or optimized or optimize) adj (promoter))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:50
S11 6	26	S114 and ((synthesized or synthetic or artificial or optimal or optimized or optimize) with (promoter))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:38
S11 7	8	S114 and ((synthesized or synthetic or artificial or optimal or optimized or optimize) with (enhancer))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:38
S11 8	25	S116 and ((enhancer))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:46
S11 9	12	S118 and (((genetic adj immunization) or (genetic adj (vaccine or vaccination)) or (DNA-based adj (vaccine or vaccination)) or (DNA adj (vaccine or vaccination)) or (gene adj therapy)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	SAME	ON	2006/04/05 17:51

EAST Search History

S12 0	10	S119 and @ad<"20030218"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:47
S12 1	10	S115 and ((enhancer))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:50
S12 2	5	S121 and (((genetic adj immunization) or (genetic adj (vaccine or vaccination)) or (DNA-based adj (vaccine or vaccination)) or (DNA adj (vaccine or vaccination)) or (gene adj therapy)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	SAME	ON	2006/04/05 17:46
S12 3	3	S122 and @ad<"20030218"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:49
S12 4	9459	(((interferon adj regulatory adj factor) or irf) adj binding adj (element or site or region)) or (((interferon adj regulatory adj factor) or irf) adj (element or site or region))) or IRF or IRF-E or IRF-1 or IRF1 or IRF2 or IRF-2 or (interferon adj regulatory adj factor))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:54
S12 5	1514	S124 and @ad<"20030218"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:56
S12 6	0	S125 and ((synthesized or synthetic or artificial or optimal or optimized or optimize) adj (promoter and enhancer))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:56
S12 7	37	S125 and ((synthesized or synthetic or artificial or optimal or optimized or optimize) adj (promoter))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:50
S12 8	37	S125 and ((synthesized or synthetic or artificial or optimized or optimize) adj (promoter))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:50

EAST Search History

S129	33	S128 and ((enhancer))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:57
S130	24	S129 and (((genetic adj immunization) or (genetic adj (vaccine or vaccination)) or (DNA-based adj (vaccine or vaccination)) or (DNA adj (vaccine or vaccination)) or (gene adj therapy)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	SAME	ON	2006/04/05 17:57
S131	4	S130 and ((TFIIB or (transcription adj factor adj IIB)) and (Tata adj box))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:58
S132	4	S130 and ((TFIIB or (transcription adj factor adj IIB)) and (Tata adj box) and (initiation or initiation))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:53
S133	3	S130 and ((TFIIB or (transcription adj factor adj IIB)) and (Tata adj box) and (initiation or initiation) and ((upstream with (binding adj element)) or (upstream with (regulatory adj element)) or (upstream with enhancer)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:53
S134	3	S130 and ((TFIIB or (transcription adj factor adj IIB)) and (Tata adj box) and (initiation or initiation) and ((upstream with (binding adj element)) or (upstream with (regulatory adj element)) or (upstream with enhancer) or (upstream with promoter)) and ((downstream with (binding adj element)) or (downstream with (regulatory adj element)) or (downstream with enhancer) or (downstream with promoter)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 18:21
S135	186	((((interferon adj regulatory adj factor) or irf) adj binding adj (element or site or region)) or (((interferon adj regulatory adj factor) or irf) adj (element or site or region))) or IRF or IRF-E or IRF-1 or IRF1 or IRF2 or IRF-2 or (interferon adj regulatory adj factor))) and (SP-1 or SP1)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/06 11:01

EAST Search History

S13 6	15	(((((interferon adj regulatory adj factor) or irf) adj binding adj (element or site or region))) or (((interferon adj regulatory adj factor) or irf) adj (element or site or region))) or IRF or IRF-E or IRF-1 or IRF1 or IRF2 or IRF-2 or (interferon adj regulatory adj factor))) and ((SP-1 or SP1) adj binding adj (region or site or element))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:56
S13 7	10	S136 and @ad<"20030218"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:59
S13 8	119	S135 and @ad<"20030218"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:56
S13 9	0	S138 and ((synthesized or synthetic or artificial or optimal or optimized or optimize) adj (promoter and enhancer))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:57
S14 0	15	S138 and ((synthesized or synthetic or artificial or optimized or optimize) adj (promoter))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:59
S14 1	1	S137 and ((synthesized or synthetic or artificial or optimized or optimize) adj (promoter))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:57
S14 2	15	S140 and ((enhancer))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:57
S14 3	1	S141 and ((enhancer))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:59

EAST Search History

S14 4	15	S142 and (((genetic adj immunization) or (genetic adj (vaccine or vaccination)) or (DNA-based adj (vaccine or vaccination)) or (DNA adj (vaccine or vaccination)) or (gene adj therapy)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	SAME	ON	2006/04/05 17:58
S14 5	1	S143 and (((genetic adj immunization) or (genetic adj (vaccine or vaccination)) or (DNA-based adj (vaccine or vaccination)) or (DNA adj (vaccine or vaccination)) or (gene adj therapy)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	SAME	ON	2006/04/05 17:58
S14 6	3	S144 and ((TFIIB or (transcription adj factor adj IIB)) and (Tata adj box))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:58
S14 7	0	S145 and ((TFIIB or (transcription adj factor adj IIB)) and (Tata adj box))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:59
S14 8	107	S135 and (((genetic adj immunization) or (genetic adj (vaccine or vaccination)) or (DNA-based adj (vaccine or vaccination)) or (DNA adj (vaccine or vaccination)) or (gene adj therapy)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	SAME	ON	2006/04/05 18:04
S14 9	74	S148 and @ad<"20030218"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 18:20
S15 0	15	S149 and ((synthesized or synthetic or artificial or optimized or optimize) adj (promoter))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 17:59
S15 1	15	S150 and ((enhancer))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 18:04
S15 2	3	S151 and ((TFIIB or (transcription adj factor adj IIB)) and (Tata adj box))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 18:20

EAST Search History

S15 3	42541	(sp1 or sp-1 or irf or IRF-1 or IRF-e or IRF-2 or (interferon adj regulatory adj factor) or (((interferon adj regulatory adj factor) or irf) adj binding adj (element or site or region)) or (((interferon adj regulatory adj factor) or irf) adj (element or site or region))) or IRF-E or IRF-1 or IRF-2) or cbp or (creb adj binding adj protein) or (Cat adj binding adj protein) or AP-1 or AP1 or (activation adj protein) or C-jun or NFkB or ("NF.kappa.B") or CREB/ATF or NF1 or NF-1)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/06 11:02
S15 4	22196	S153 and @ad<"20030218"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 18:03
S15 5	368	S154 and ((synthesized or synthetic or artificial or optimized or optimize) adj (promoter))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 18:05
S15 6	308	S155 and ((enhancer))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 18:21
S15 7	233	S156 and (((genetic adj immunization) or (genetic adj (vaccine or vaccination)) or (DNA-based adj (vaccine or vaccination)) or (DNA adj (vaccine or vaccination)) or (gene adj therapy)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	SAME	ON	2006/04/05 18:20
S15 8	227	S157 and ((synthesized or synthetic or artificial) adj (promoter))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 18:15
S15 9	8	S157 and ((optimized or optimize) adj (promoter))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 18:15

EAST Search History

S16 0	2	S158 and ((optimized or optimize) adj (promoter))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/06 08:46
S16 1	149	S157 and ((synthesized or synthetic) adj (promoter))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 18:15
S16 2	0	S161 and ((optimized or optimize) adj (promoter))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 18:15
S16 3	3	S157 and ((synthesized or synthetic or artificial) adj (enhancer))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 18:18
S16 4	1273	((synthesized or synthetic or artificial or optimal or optimized or optimize) adj (promoter)) and (spacer or (spacer adj region) or intron)	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 18:19
S16 5	813	S164 and @ad<"20030218"	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 18:20
S16 6	459	S165 and (((genetic adj immunization) or (genetic adj (vaccine or vaccination)) or (DNA-based adj (vaccine or vaccination)) or (DNA adj (vaccine or vaccination)) or (gene adj therapy)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	SAME	ON	2006/04/05 18:20
S16 7	6	S166 and ((TFIIB or (transcription adj factor adj IIB)) and (Tata adj box))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 18:20

EAST Search History

S16 9	0	S139 and ((TFIIB or (transcription adj factor adj IIB)) and (Tata adj box) and (initiation or initiation) and ((upstream with (binding adj element)) or (upstream with (regulatory adj element)) or (upstream with enhancer) or (upstream with promoter)) and ((downstream with (binding adj element)) or (downstream with (regulatory adj element)) or (downstream with enhancer) or (downstream with promoter)))	US-PGPUB; USPAT; USOCR; EPO; JPO; DERWENT	OR	ON	2006/04/05 18:21
----------	---	--	---	----	----	------------------

10/781,055 LLM
Dialog 4/6/06

Trying 31060000009999...Open

DIALOG INFORMATION SERVICES

PLEASE LOGON:

***** HHHHHHHH SSSSSSSS? ### Status: Signing onto Dialog *****

ENTER PASSWORD:

***** HHHHHHHH SSSSSSSS? *****

Status: Login successfulWelcome to DIALOG

Dialog level 05.10.03D

Last logoff: 03apr06 08:53:01

Logon file405 06apr06 10:08:28

*** ANNOUNCEMENTS ***

NEW FILES RELEASED

***Regulatory Affairs Journals (File 183)

***Index Chemicus (File 302)

***Inspec (File 202)

RELOADS COMPLETED

*** MEDLINE has been reloaded with the 2006 MeSH (Files 154 & 155)

*** The 2005 reload of the CLAIMS files (Files 340, 341, 942)

is now available online.

RESUMED UPDATING

***EDGARPLUS(TM)-Williams Act Filings (File 773)

***EDGARPLUS(TM)-Prospectuses (File 774)

***EDGARPLUS(TM)-Registration Statements (File 775)

***EDGARPLUS(TM)-6K, 8K, and 10C Filings (File 776)

***EDGARPLUS(TM)-10-K & 20F Filings (File 778)

***EDGARPLUS(TM)-10-Q Filings (File 779)

***EDGARPLUS(TM)-Proxy Statements (File 780)

Chemical Structure Searching now available in Prous Science Drug Data Report (F452), Prous Science Drugs of the Future (F453), IMS R&D Focus (F445/955), Pharmaprojects (F128/928), Beilstein Facts (F390), Derwent Chemistry Resource (F355) and Index Chemicus (File 302).

>>>For the latest news about Dialog products, services, content<<<

>>>and events, please visit What's New from Dialog at <<<

>>><http://www.dialog.com/whatsnew/>. You can find news about<<<

>>>a specific database by entering HELP NEWS <file number>.<<<

* * *

SYSTEM:HOME

Cost is in DialUnits

Menu System II: D2 version 1.7.9 term=ASCII

*** DIALOG HOMEBASE(SM) Main Menu ***

Information:

1. Announcements (new files, reloads, etc.)
2. Database, Rates, & Command Descriptions
3. Help in Choosing Databases for Your Topic
4. Customer Services (telephone assistance, training, seminars, etc.)
5. Product Descriptions

Connections:

6. DIALOG(R) Document Delivery
7. Data Star(R)

(c) 2003 Dialog, a Thomson business. All rights reserved.

/H = Help

/L = Logoff

/NOMENU = Command Mode

Enter an option number to view information or to connect to an online service. Enter a BEGIN command plus a file number to search a database (e.g., B1 for ERIC).

?

Terminal set to DLINK

*** DIALOG HOMEBASE(SM) Main Menu ***

Information:

1. Announcements (new files, reloads, etc.)
2. Database, Rates, & Command Descriptions
3. Help in Choosing Databases for Your Topic
4. Customer Services (telephone assistance, training, seminars, etc.)
5. Product Descriptions

Connections:

6. DIALOG(R) Document Delivery
7. Data Star(R)

(c) 2003 Dialog, a Thomson business. All rights reserved.

/H = Help

/L = Logoff

/NOMENU = Command Mode

Enter an option number to view information or to connect to an online service. Enter a BEGIN command plus a file number to search a database (e.g., B1 for ERIC).

? b biosci

```
>>>          44 is unauthorized
>>>          76 is unauthorized
>>>2 of the specified files are not available
      06apr06 10:08:51 User276741 Session D121.1
      $0.00    0.209 DialUnits FileHomeBase
      $0.00 Estimated cost FileHomeBase
      $0.10 TELNET
      $0.10 Estimated cost this search
      $0.10 Estimated total session cost 0.209 DialUnits
```

SYSTEM:OS - DIALOG OneSearch

```
File 5:Biosis Previews(R) 1969-2006/Apr W1
      (c) 2006 BIOSIS
File 24:CSA Life Sciences Abstracts 1966-2006/Feb
      (c) 2006 CSA.
File 28:Oceanic Abstracts 1966-2006/Feb
      (c) 2006 CSA.
File 34:SciSearch(R) Cited Ref Sci 1990-2006/Mar W4
      (c) 2006 Inst for Sci Info
File 35:Dissertation Abs Online 1861-2006/Mar
      (c) 2006 ProQuest Info&Learning
File 40:Enviroline(R) 1975-2006/Jan
File 41:Pollution Abstracts 1966-2006/Feb
      (c) 2006 CSA.
File 50:CAB Abstracts 1972-2006/Mar
      (c) 2006 CAB International
File 65:Inside Conferences 1993-2006/Apr 05
```

(c) 2006 BLDSC all rts. reserv.
 File 71:ELSEVIER BIOBASE 1994-2006/Apr W1
 (c) 2006 Elsevier Science B.V.
 File 73:EMBASE 1974-2006/Apr 06
 (c) 2006 Elsevier Science B.V.
 File 91:MANTIS(TM) 1880-2006/Feb
 2006 (c) Action Potential
 File 94:JICST-EPlus 1985-2006/Jan W2
 (c)2006 Japan Science and Tech Corp(JST)
 File 98:General Sci Abs 1984-2004/Dec
 (c) 2005 The HW Wilson Co.
 File 110:WasteInfo 1974-2002/Jul
 (c) 2002 AEA Techn Env.
***File 110: This file is closed (no updates)**
 File 135:NewsRx Weekly Reports 1995-2006/Mar W4
 (c) 2006 NewsRx
***File 135: Please see HELP NEWS135 for information on select journal titles.**
 File 136:BioEngineering Abstracts 1966-2006/Feb
 (c) 2006 CSA.
 File 143:Biol. & Agric. Index 1983-2006/Mar
 (c) 2006 The HW Wilson Co
 File 144:Pascal 1973-2006/Mar W2
 (c) 2006 INIST/CNRS
 File 155:MEDLINE(R) 1951-2006/Apr 06
 (c) format only 2006 Dialog
***File 155: Medline has been reloaded. Some accession numbers have changed.**
 File 164:Allied & Complementary Medicine 1984-2006/Apr
 (c) 2006 BLHCIS
 File 172:EMBASE Alert 2006/Apr 06
 (c) 2006 Elsevier Science B.V.
 File 185:Zoological Record Online(R) 1978-2006/Apr
 (c) 2006 BIOSIS
 File 357:Derwent Biotech Res. _1982-2006/Mar W4
 (c) 2006 Thomson Derwent & ISI
 File 369:New Scientist 1994-2006/Aug W4
 (c) 2006 Reed Business Information Ltd.
 File 370:Science 1996-1999/Jul W3
 (c) 1999 AAAS
***File 370: This file is closed (no updates). Use File 47 for more current information.**
 File 391:Beilstein Reactions 2005/Q3
 (c) 2005 Beilstein GmbH
 File 434:SciSearch(R) Cited Ref Sci 1974-1989/Dec
 (c) 1998 Inst for Sci Info
 File 467:ExtraMED(tm) 2000/Dec
 (c) 2001 Informania Ltd.
***File 467: F467 will close on February 1, 2006.**

7.

Set	Items	Description
?	s	((synthesized or synthetic or artificial or optimized or optimize)(w)
	(promoter and enhancer))	
	804188	SYNTHESIZED
	1166292	SYNTHETIC
	1033333	ARTIFICIAL
	237542	OPTIMIZED
	131399	OPTIMIZE
	778601	PROMOTER
	172231	ENHANCER

S1 234 ((SYNTHESIZED OR SYNTHETIC OR ARTIFICIAL OR OPTIMIZED OR OPTIMIZE) (W) (PROMOTER AND ENHANCER))
 ? s s1 and (((genetic (w) immunization) or (genetic (w) (vaccine or vaccination)) or (DNA-based (w) (vaccine or vaccination)) or (DNA (w) (vaccine or vaccination)) or (gene (w) therapy)))

Processing

Processed 10 of 29 files ...

Processing

Processed 20 of 29 files ...

Completed processing all files

234 S1
 3677542 GENETIC
 394595 IMMUNIZATION
 3222 GENETIC (W) IMMUNIZATION
 3677542 GENETIC
 559059 VACCINE
 362892 VACCINATION
 2586 GENETIC (W) (VACCINE OR VACCINATION)
 700 DNA-BASED
 559059 VACCINE
 362892 VACCINATION
 0 DNA-BASED (W) (VACCINE OR VACCINATION)
 4834543 DNA
 559059 VACCINE
 362892 VACCINATION
 21780 DNA (W) (VACCINE OR VACCINATION)
 5991666 GENE
 8269902 THERAPY
 232644 GENE (W) THERAPY
 S2 25 S1 AND (((GENETIC (W) IMMUNIZATION) OR (GENETIC (W) (VACCINE OR VACCINATION)) OR (DNA-BASED (W) (VACCINE OR VACCINATION)) OR (DNA (W) (VACCINE OR VACCINATION)) OR (GENE (W) THERAPY)))
 ? s s2 and ((optimized or optimize) (w) (promoter and enhancer))
 25 S2
 237542 OPTIMIZED
 131399 OPTIMIZE
 778601 PROMOTER
 172231 ENHANCER
 19 (OPTIMIZED OR OPTIMIZE) (W) (PROMOTER AND ENHANCER)
 S3 9 S2 AND ((OPTIMIZED OR OPTIMIZE) (W) (PROMOTER AND ENHANCER))

? rd

>>>Duplicate detection is not supported for File 391.

>>>Records from unsupported files will be retained in the RD set.

S4 2 RD (unique items)

? t s4/free/1-2

4/8/1 (Item 1 from file: 5)
 0012249309 BIOSIS NO.: 199900508969
 Gene therapy **expression vectors based on the clotting Factor IX promoter**
 1999

4/8/2 (Item 1 from file: 73)
 11523901 EMBASE No: 2002095400
Molecular engineering of a two-step transcription amplification (TSTA) system for transgene delivery in prostate cancer

2002

? t s4/ medium,k/free
>>>'FREE' not recognized as item list
? t s4/ medium,k/1-2

4/K/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)
(c) 2006 BIOSIS. All rts. reserv.

0012249309 BIOSIS NO.: 199900508969

Gene therapy expression vectors based on the clotting Factor IX
promoter

AUTHOR: Hoag H; Gore J; Barry D; Mueller C R (Reprint)
AUTHOR ADDRESS: Cancer Research Laboratories, Queen's University, 3rd Floor
Botterell Hall, Kingston, ON, K7L 3N6, Canada**Canada
JOURNAL: Gene Therapy 6 (9): p1584-1589 Sept., 1999 1999
MEDIUM: print
ISSN: 0969-7128
DOCUMENT TYPE: Article
RECORD TYPE: Abstract
LANGUAGE: English

Gene therapy expression vectors based on the clotting Factor IX
promoter

ABSTRACT: The liver is one of the prime targets for gene therapy , and
the correction of defects in a variety of clotting factor genes is one of
...

...structure of the clotting Factor IX gene to design optimized expression
vectors for use in gene therapy . The activity of the proximal
promoter has been augmented by the introduction of a multimerized...

...the proximal promoter alone when assayed in the human liver cell line
Hep G2. This optimized promoter is significantly more active than the
SV40 enhancer/early promoter. The expression of the optimized...

DESCRIPTORS:

...ORGANISMS: PARTS ETC: digestive system, gene therapy target
METHODS & EQUIPMENT: gene therapy --

4/K/2 (Item 1 from file: 73)

DIALOG(R)File 73:EMBASE
(c) 2006 Elsevier Science B.V. All rts. reserv.

11523901 EMBASE No: 2002095400

Molecular engineering of a two-step transcription amplification (TSTA)
system for transgene delivery in prostate cancer

Zhang L.; Adams J.Y.; Billick E.; Ilagan R.; Iyer M.; Le K.; Smallwood A.
; Gambhir S.S.; Carey M.; Wu L.
M. Carey, Department of Biological Chemistry, University of California,
Los Angeles School of Medicine, Box 1737, Los Angeles, CA 90095-1737
United States

AUTHOR EMAIL: mcarey@mednet.ucla.edu

Molecular Therapy (MOL. THER.) (United States) 2002, 5/3 (223-232)

CODEN: MTOHC ISSN: 1525-0016

DOCUMENT TYPE: Journal ; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 44

Gene therapy is founded on the concept that tissue-specific promoters can express heterologous genes for molecular...

...varied over an 800-fold range. We also found that a single plasmid bearing the **optimized enhancer**, GAL4-VP16 derivative, and reporter expressed firefly luciferase at 20-fold higher levels than the...

MEDICAL DESCRIPTORS:

transgene; genetic engineering; gene amplification; gene targeting; **gene therapy**; promoter region; heterologous expression; transcription initiation; target cell; enhancer region; reporter gene; DNA template; protein...

? s (((synthesized or synthetic or engineered) and (optimized or optimize)) (s) (promoter and enhancer))

804188 SYNTHESIZED
1166292 SYNTHETIC
144724 ENGINEERED
237542 OPTIMIZED
131399 OPTIMIZE
778601 PROMOTER
172231 ENHANCER

S5 55 (((SYNTHESIZED OR SYNTHETIC OR ENGINEERED) AND (OPTIMIZED OR OPTIMIZE)) (S) (PROMOTER AND ENHANCER))

? s s5 and (((genetic (w) immunization) or (genetic (w) (vaccine or vaccination)) or (DNA-based (w) (vaccine or vaccination)) or (DNA (w) (vaccine or vaccination)) or (gene (w) therapy)))

Processing

Processed 10 of 29 files ...

Processing

Processed 20 of 29 files ...

Completed processing all files

55 S5
3677542 GENETIC
394595 IMMUNIZATION
3222 GENETIC(W)IMMUNIZATION
3677542 GENETIC
559059 VACCINE
362892 VACCINATION
2586 GENETIC(W) (VACCINE OR VACCINATION)
700 DNA-BASED
559059 VACCINE
362892 VACCINATION
0 DNA-BASED(W) (VACCINE OR VACCINATION)
4834543 DNA
559059 VACCINE
362892 VACCINATION
21780 DNA(W) (VACCINE OR VACCINATION)
5991666 GENE
8269902 THERAPY
232644 GENE(W)THERAPY

S6 19 S5 AND (((GENETIC (W) IMMUNIZATION) OR (GENETIC (W) (VACCINE OR VACCINATION)) OR (DNA-BASED (W) (VACCINE OR VACCINATION)) OR (DNA (W) (VACCINE OR VACCINATION)) OR (GENE (W) THERAPY)))

? rd

>>>Duplicate detection is not supported for File 391.

>>>Records from unsupported files will be retained in the RD set.

S7 9 RD (unique items)

? s s7 not pd>030218

>>>One or more prefixes are unsupported

>>> or undefined in one or more files.

9 S7
7641278 PD>030218
S8 7 S7 NOT PD>030218
? t s8/free/1-7

8/8/1 (Item 1 from file: 5)
0014781401 BIOSIS NO.: 200400148062
Toward safe and efficient hemophilia A gene therapy .
2003

8/8/2 (Item 2 from file: 5)
0014664618 BIOSIS NO.: 200400035375
Development of artificial chimerical gene regulatory elements specific for cancer gene therapy .
2003

8/8/3 (Item 3 from file: 5)
0012726970 BIOSIS NO.: 200000445283
Transfer and expression of foreign genes in mammalian cells
2000

8/8/4 (Item 4 from file: 5)
0011024831 BIOSIS NO.: 199799658891
Development of improved vectors for DNA-based immunization and other gene therapy applications
1997

8/8/5 (Item 1 from file: 144)
DIALOG(R)File 144:(c) 2006 INIST/CNRS. All rts. reserv.

16430476 PASCAL No.: 04-0071230
Development of artificial chimerical gene regulatory elements specific for cancer gene therapy
2003

English Descriptors: Malignant tumor; **Gene therapy** ; Treatment; Hybrid gene; Transcription promoter; Regulatory sequence; Protooncogene; C-Onc gene; Cyclin E; Hexokinase; Isozyme; RNA-directed DNA polymerase; Catalytic subunit; Synthetic product; In vitro; Human
Broad Descriptors: Transferases; Enzyme; Nucleotidyltransferases; Genetics; Transferases; Enzyme; Nucleotidyltransferases; Genetique; Transferases; Enzima; Nucleotidyltransferases; Genetica

French Descriptors: Tumeur maligne; Therapie genique; Traitement; Gene hybride; Promoteur transcription; Sequence regulatrice; Protooncogene; Gene onc cellulaire; Cycline E; Hexokinase; Isozyme; RNA-directed DNA polymerase; Sousunite catalytique; Produit synthetique; In vitro; Homme; Phosphatase Cdc25A; Gene H-ras; Gene ras

Classification Codes: 002B04H04
Copyright (c) 2004 INIST-CNRS. All rights reserved.

8/8/6 (Item 1 from file: 357)

0294670 DBR Accession No.: 2002-16517

Novel human cytomegalovirus Intron A fragment for use in expression constructs, lacks full-length Intron A sequence, and enhance expression levels when present in expression constructs - vector plasmid pCMVII-mediated recombinant protein gene transfer and expression in host cell for use in cancer diagnosis, prevention, therapy and gene therapy 2002

8/8/7 (Item 2 from file: 357)

0290874 DBR Accession No.: 2002-12721

Preparing a synthetic nucleic acid molecule with reduced inappropriate transcriptional characteristics when expressed in a cell, for e.g making fusion proteins, by altering a wild type or another synthetic nucleic acid sequence - recombinant enzyme gene production, vector expression in host cell, promoter, selectable marker useful in gene therapy , gene expression level measurement and pharmaceutical development 2002

? t s8/medium,k/1-7

8/K/1 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 BIOSIS. All rts. reserv.

0014781401 BIOSIS NO.: 200400148062

Toward safe and efficient hemophilia A gene therapy .

AUTHOR: Hawley Robert G (Reprint); Moayeri Morvarid (Reprint); Ramezani Ali (Reprint); Morgan Richard A; Hawley Teresa S (Reprint)

AUTHOR ADDRESS: Holland Laboratory, American Red Cross, Rockville, MD, USA
**USA

JOURNAL: Blood 102 (11): p742a November 16, 2003 2003

MEDIUM: print

CONFERENCE/MEETING: 45th Annual Meeting of the American Society of Hematology San Diego, CA, USA December 06-09, 2003; 20031206

SPONSOR: American Society of Hematology

ISSN: 0006-4971

DOCUMENT TYPE: Meeting; Meeting Poster; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

Toward safe and efficient hemophilia A gene therapy .

...ABSTRACT: delivery, suboptimal expression of fVIII mRNA and inefficient secretion of fVIII protein in the genetically- **engineered** cells, plus the development of inhibitory antibodies to fVIII neoantigen. Moreover, in view of recent...

...containing strong transcriptional control elements such as the MSCV LTR and the human EF1 a **promoter** ; inclusion of introns for more efficient processing and accumulation of fVIII mRNA; construction of secretion...

...incorporation of chromatin insulators to minimize position effect variegation and transgene silencing as well as **enhancer** -mediated oncogene activation. After these improvements, we comparatively examined a variety of hematopoietic and nonhematopoietic...

...mesenchymal stem cells (36+-2 ng/mL/106cells/24 hrs). Nonetheless, the recombinant fVIII molecules **synthesized** by transfused endothelial and mesenchymal stem cells may still stimulate production of inhibitory antibodies. By...

...immunocompromised (El2; fVIII exon 16 and B7-2 disrupted) hemophilic mice were transduced with an **optimized** MSCV-based splice-gag oncoretroviral vector containing an sfVIII-IRES-EGFP cassette. Transplantation of 2...

DESCRIPTORS:

...METHODS & EQUIPMENT: **gene therapy** --

8/K/2 (Item 2 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 BIOSIS. All rts. reserv.

0014664618 BIOSIS NO.: 200400035375

Development of artificial chimerical gene regulatory elements specific for cancer gene therapy .

AUTHOR: Shin June Ho; Yi Jea Kyu; Lee Young Jin; Kim Ae Li; Park Mi Ae; Kim Sung-Hyun; Lee Heuiran; Kim Chul Geun (Reprint)

AUTHOR ADDRESS: Department of Life Science, College of Natural Sciences, Hanyang University, Haengdang 17, Sungdong-gu, Seoul, 133-791, South Korea**South Korea

AUTHOR E-MAIL ADDRESS: cgkim@hanyang.ac.kr

JOURNAL: Oncology Reports 10 (6): p2063-2069 November-December 2003 2003

MEDIUM: print

ISSN: 1021-335X

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

Development of artificial chimerical gene regulatory elements specific for cancer gene therapy .

...ABSTRACT: as minimizing inappropriate gene expression in non-target cells. To accomplish this goal for cancer **gene therapy** , we have evaluated the potential of cancer specific gene expression of functional **promoter / enhancer** elements in six putative cancer-specific genes (Tcflalpha, C-Ha-Ras, CyclinE, Cdc25A, HK II...

...have also constructed a series of artificial chimerical regulatory elements by combinatorial linking of E **promoter** and T **enhancer** . A dramatic decrease of activity was observed as the copy number of concatenated T/E...

...cancer cell lines of different origins. Our results demonstrate that although the transcriptional activities of **synthetic** promoters are weak, some cancer-specific regulatory elements are useful in developing **optimized** and systemic cancer-specific regulatory regions with potential application in targeted cancer cell therapy.

DESCRIPTORS:

METHODS & EQUIPMENT: cancer **gene therapy** --

8/K/3 (Item 3 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 BIOSIS. All rts. reserv.

0012726970 BIOSIS NO.: 200000445283

Transfer and expression of foreign genes in mammalian cells

AUTHOR: Colosimo A; Goncz K K; Holmes A R; Kunzelmann K; Novelli G; Malone R W; Bennett M J; Gruenert D C (Reprint)

AUTHOR ADDRESS: Human Molecular Genetics Unit, Department of Medicine,
Colchester Research Facility, University of Vermont, 208 S. Park Dr.,
Suite 2, Colchester, VT, 05446, USA**USA

JOURNAL: Biotechniques 29 (2): p314-331 August, 2000 2000

MEDIUM: print

ISSN: 0736-6205

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

...ABSTRACT: of the functional significance of genes and regulatory sequences as well as the development of **gene therapy** strategies. To this end, different mammalian expression vector systems have been designed. The choice of...

...study and will involve selecting particular parameters of expression systems such as the type of **promoter / enhancer** sequences, the type of expression (transient versus stable) and the level of desired expression. In...

...viral strategies. While these systems have all been effective in vitro they need to be **optimized** for individual cell types and, in particular, for in vivo transfection.

8/K/4 (Item 4 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2006 BIOSIS. All rts. reserv.

0011024831 BIOSIS NO.: 199799658891

Development of improved vectors for DNA-based immunization and other gene therapy applications

AUTHOR: Norman Jon A (Reprint); Hobart Peter; Manthorpe Marston; Felgner Phil; Wheeler Carl

AUTHOR ADDRESS: Vical Inc., 9373 Towne Center Dr. Ste. 100, San Diego, CA 92121, USA**USA

JOURNAL: Vaccine 15 (8): p801-803 1997 1997

ISSN: 0264-410X

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

Development of improved vectors for DNA-based immunization and other gene therapy applications

...ABSTRACT: steps in the production of vectors for DNA-based immunization as well as for other **gene therapy** applications. A mouse muscle/reporter gene assay system was used to systematically improve a plasmid DNA vector. The **optimized** vector VR1255 contained: (1) CMV **promoter** and **enhancer** ; (2) CMV IE Intron A; (3) kanamycin resistance gene; (4) deleted SV40 origin of replication; (5) **optimized** lux coding region; and (6) a minimal **synthetic** terminator from the rabbit beta globin gene, mRBG. The vector VR1255 expressed 137 times greater...

...an earlier prototype RSV-based vector. For plasmid vector delivery into nonmuscle tissues, a recently **synthesized** cationic lipid, GAP-DLRIE, was found to greatly enhance the uptake and expression of plasmid...

DESCRIPTORS:

MISCELLANEOUS TERMS: ... **GENE THERAPY** ;

8/K/5 (Item 1 from file: 144)
DIALOG(R) File 144:Pascal
(c) 2006 INIST/CNRS. All rts. reserv.

16430476 PASCAL No.: 04-0071230
Development of artificial chimerical gene regulatory elements specific for cancer gene therapy
JUNE HO SHIN; JEA KYU YI; YOUNG JIN LEE; AE LI KIM; MI AE PARK; KIM Sung-Hyun; LEE Heuiran; CHUL GEUN KIM
Department of Life Science and Research Institute of Natural Sciences, College of Natural Sciences, Hanyang University, Seoul 133-791, Korea, Republic of; Department of Microbiology, University of Ulsan College of Medicine, Seoul 138-736, Korea, Republic of
Journal: Oncology reports, 2003, 10 (6) 2063-2069
Language: English

Copyright (c) 2004 INIST-CNRS. All rights reserved.

Development of artificial chimerical gene regulatory elements specific for cancer gene therapy
... as minimizing inappropriate gene expression in non-target cells. To accomplish this goal for cancer **gene therapy**, we have evaluated the potential of cancer specific gene expression of functional **promoter / enhancer** elements in six putative cancer-specific genes (Tcfl alpha, C-Ha-Ras, CyclinE, Cdc25A, HK...
... have also constructed a series of artificial chimerical regulatory elements by combinatorial linking of E **promoter** and T **enhancer**. A dramatic decrease of activity was observed as the copy number of concatenated T/E...

... cancer cell lines of different origins. Our results demonstrate that although the transcriptional activities of **synthetic** promoters are weak, some cancer-specific regulatory elements are useful in developing **optimized** and systemic cancer-specific regulatory regions with potential application in targeted cancer cell therapy.

English Descriptors: Malignant tumor; **Gene therapy**; Treatment; Hybrid gene; Transcription promoter; Regulatory sequence; Protooncogene; C-Onc gene; Cyclin E; Hexokinase; Isozyme...

8/K/6 (Item 1 from file: 357)
DIALOG(R) File 357:Derwent Biotech Res.
(c) 2006 Thomson Derwent & ISI. All rts. reserv.

0294670 DBR Accession No.: 2002-16517 PATENT
Novel human cytomegalovirus Intron A fragment for use in expression constructs, lacks full-length Intron A sequence, and enhance expression levels when present in expression constructs - vector plasmid pCMVII-mediated recombinant protein gene transfer and expression in host cell for use in cancer diagnosis, prevention, therapy and gene therapy
AUTHOR: THUDIUM K; SELBY M; ULMER J
PATENT ASSIGNEE: CHIRON CORP 2002
PATENT NUMBER: WO 200231137 PATENT DATE: 20020418 WPI ACCESSION NO.: 2002-454551 (200248)
PRIORITY APPLIC. NO.: US 240502 APPLIC. DATE: 20001013
NATIONAL APPLIC. NO.: WO 2001US32050 APPLIC. DATE: 20011012
LANGUAGE: English

...gene transfer and expression in host cell for use in cancer diagnosis, prevention, therapy and gene therapy

...ABSTRACT: cytomegalovirus (hCMV) Intron A fragment (I) (derived from intron A sequence of CMV immediate-early **enhancer / promoter** region), where (I) lacks the full-length (II) and comprises a sequence of nucleotides having...

... 2) a host cell (IV) comprising (III); and (3) a polynucleotide comprising a 127 nucleotide **optimized** rabbit beta-globin gene sequence (S6), given in the specification. BIOTECHNOLOGY - Preferred Fragment: (I) comprising...

... preferably consists of (S3). Preferred Expression Construct: In (III), the control elements further comprise a **promoter** such as simian virus (SV)40 early **promoter**, CMV **promoter**, mouse mammary tumor virus long terminal repeat (LTR) **promoter**, an adenovirus major late **promoter**, an respiratory syncytial virus (RSV) **promoter**, a SRalpha **promoter**, or a herpes simplex virus **promoter**. Preferably, the control elements further comprise the hCMV IE1 **enhancer / promoter** region found at nucleotide positions 460-1264 of a 2170 nucleotide sequence (S4), given in...

... the nucleotide sequence of the 5' region of major IE gene of hCMV including the **enhancer / promoter** region), and the control elements further comprise Exon 2 of 5'-untranslated region (UTR) comprising the sequence of nucleotides at positions 821-834 of (S1). ACTIVITY - Cytostatic. MECHANISM OF ACTION - **Gene therapy**. In order to test the ability of the Intron A fragments to direct transcription in...

... diagnosis of a wide variety of diseases. (III) is used in nucleic acid immunization and **gene therapy**. ADMINISTRATION - (III) is administered by standard **gene therapy** technique. ADVANTAGE - When (I) is present in a (C), the (C) achieves expression levels at...sites. The expression constructs were linked to the firefly luciferase gene or to a codon- **optimized** human immunodeficiency virus (HIV) p55gag gene. The initial deletion of Intron A was prepared by means of substituting a 778 base pair NsiI-SalI fragment from plasmid pCMVkmLuc with a **synthetic** oligonucleotide (having a fully defined sequence of 100 nucleotides as given in the specification) that restored the last 80 nucleotides of Intron A (with **optimized** branch point and polypyrimidine tract together with Exon 2 of the 5'-untranslated region (UTR...

... pair deletion from Intron A. The resulting expression plasmid, pCON3, contained the human cytomegalovirus (hCMV) **enhancer / promoter** region with a 130 base pair Intron A fragment. Twelve additional Intron A deletion constructs...

... divested with SalI-XbaI to generate recipient vector fragments for the insertion of the codon- **optimized** HIVp55gag gene obtained by digestion of plasmid pCMVkm2.GAGmod.SF2. (44 pages)

DESCRIPTORS: ...vector plasmid pCMVII-mediated gene transfer, expression in host cell, appl. cancer diagnosis, prevention, therapy, **gene therapy** animal mammal herpes virus tumor cytostatic DNA sequence protein sequence (21, 46)

...SECTION: DIAGNOSTICS-Molecular Diagnostics; THERAPEUTICS- **Gene Therapy**

8/K/7 (Item 2 from file: 357)

DIALOG(R) File 357:Derwent Biotech Res.

(c) 2006 Thomson Derwent & ISI. All rts. reserv.

0290874 DBR Accession No.: 2002-12721 PATENT

Preparing a synthetic nucleic acid molecule with reduced inappropriate transcriptional characteristics when expressed in a cell, for e.g making fusion proteins, by altering a wild type or another synthetic nucleic acid sequence - recombinant enzyme gene production, vector expression in host cell, promoter, selectable marker useful in gene therapy, gene expression level measurement and pharmaceutical development

AUTHOR: WOOD K V; WOOD M G; ZHUANG Y; PAGUIO A

PATENT ASSIGNEE: PROMEGA CORP 2002

PATENT NUMBER: WO 200216944 PATENT DATE: 20020228 WPI ACCESSION NO.: 2002-304140 (200234)

PRIORITY APPLIC. NO.: US 645706 APPLIC. DATE: 20000824

NATIONAL APPLIC. NO.: WO 2001US26566 APPLIC. DATE: 20010824

LANGUAGE: English

...sequence - recombinant enzyme gene production, vector expression in host cell, promoter, selectable marker useful in gene therapy, gene expression level measurement and pharmaceutical development

ABSTRACT: DERWENT ABSTRACT: NOVELTY - Preparing (I) a **synthetic** nucleic acid (sNA) molecule, involving altering several transcription regulatory sequences (TRS) in a parent (wild type or another **synthetic**) NA sequence, encoding a 100 amino acid polypeptide, to yield a sNA with a decreased...

... where the TRS are transcription factor binding sequences, intron splice sites, poly(A) addition sites, **enhancer** sequences and **promoter** sequences; and (b) altering greater than 25% of the codons in the sNA sequence which...

... 2) a plasmid comprising (II); (3) an expression vector (III) comprising (II) linked to a **promoter** functional in a cell; (4) a host cell comprising (III); (5) a reporter gene expression kit comprising (III), in a suitable container; (6) an isolated polypeptide encoded by **synthetic** green (GR) click beetle luciferase NA sequence, GRver5.1 or red (RD) click beetle luciferase...

... in the parent NA sequence, where the two set of codons are different, and the **synthetic** and the further sNA molecules encode the same polypeptide; and (10) a vector comprising (II)...

... sequence. Preferred Vector: In (III), (II) is operatively linked to a Kozak consensus sequence. The **promoter** is functional in a mammalian, preferably human, or a plant cell. (III) further comprises a multiple cloning site positioned between the **promoter** and (II). USE - (I) is useful for preparing sNA molecules which are efficiently expressed as ...

... undesirable restriction sites, ribosomal binding sites and secondary structural motifs such as hairpin loops. The **synthetic** genes encode the same protein but have improved codon usage while being largely devoid of the level of expression of the protein e.g. the **synthetic** luciferase genes permit detection of weak **promoter** activity. The **synthetic** genes are useful to express fusion proteins, to detect and/or measure the level of...

...genetic elements and in multi-well formats. (I) has applications in life science research, agro genetics, **gene therapy**, developmental science and pharmaceutical development. ADVANTAGE - (I) reduces the risk of

undesirable interactions of NA...

... acid substitutions A224H, S247H, N346I, and H348Q. Using YG81-6G01 as a parent gene, two **synthetic** gene sequences were designed. One encoded for a luciferase emitting green luminescence (GR) and one for a luciferase emitting red luminescence (RD). Both genes were designed to: (a) have **optimized** codon usage for expression in mammalian cells; (b) have a reduced number of transcriptional regulatory...

... Kozak sequence or restriction enzyme recognition sites, were identified and introduced. The process for designing **synthetic** GR and RD gene sequences involved **optimized** codon usage and changed A224V to create GRver1, separately changed A224H, S247H, H348Q and N346I...

... creating GRver5 and RDver5. The actual genes were constructed by polymerase chain reaction (PCR) using **synthetic** oligonucleotides corresponding to fragments of GRver5 and RDver5 designed sequences, creating GR6 and RD7. GR6...

DESCRIPTORS: ...appl. gene expression level measurement, subcellular localization, in vivo imaging, regulatory pathway, genetic element analysis, **gene therapy**, pharmaceutical development enzyme mammal animal DNA sequence protein sequence (21, 39)

...SECTION: GENETIC TECHNIQUES and APPLICATIONS-Gene Expression Techniques and Analysis; THERAPEUTICS- **Gene Therapy** -

? s (Tata (w) box) and (initiation or initiate) and (TFIIB or (transcription (w) factor (w) IIB)) and (upstream (w) regulatory) and ((downstream (w) regulatory) or (downstream (w) promoter (w) (element or site or region)))
Processing

Processed 10 of 29 files ...

Completed processing all files

	58187	TATA
	250744	BOX
	31533	TATA(W)BOX
	638255	INITIATION
	151672	INITIATE
	4630	TFIIB
	1556031	TRANSCRIPTION
	5472768	FACTOR
	78310	IIB
	811	TRANSCRIPTION(W)FACTOR(W)IIB
	311345	UPSTREAM
	937737	REGULATORY
	7581	UPSTREAM(W)REGULATORY
	334581	DOWNSTREAM
	937737	REGULATORY
	754	DOWNSTREAM(W)REGULATORY
	334581	DOWNSTREAM
	778601	PROMOTER
	2224532	ELEMENT
	3158871	SITE
	5530878	REGION
	339	DOWNSTREAM(W)PROMOTER(W)((ELEMENT OR SITE) OR REGION)
S9	0	(TATA (W) BOX) AND (INITIATION OR INITIATE) AND (TFIIB OR (TRANSCRIPTION (W) FACTOR (W) IIB)) AND (UPSTREAM (W) REGULATORY) AND ((DOWNSTREAM (W) REGULATORY) OR (DOWNSTREAM (W) PROMOTER (W) (ELEMENT OR SITE OR REGION)))

? ds

Set	Items	Description
S1	234	((SYNTHESIZED OR SYNTHETIC OR ARTIFICIAL OR OPTIMIZED OR -


```

        OPTIMIZE) (W) (PROMOTER AND ENHANCER))
S2      25  S1 AND (((GENETIC (W) IMMUNIZATION) OR (GENETIC (W) (VACCI-
        NE OR VACCINATION)) OR (DNA-BASED (W) (VACCINE OR VACCINATION-
        )) OR (DNA (W) (VACCINE OR VACCINATION)) OR (GENE (W) THERAPY-
        )))
S3      9   S2 AND (( OPTIMIZED OR OPTIMIZE) (W) (PROMOTER AND ENHANCER-
        ))
S4      2   RD (unique items)
S5      55  (((SYNTHESIZED OR SYNTHETIC OR ENGINEERED) AND (OPTIMIZED -
        OR OPTIMIZE)) (S) (PROMOTER AND ENHANCER))
S6      19  S5 AND (((GENETIC (W) IMMUNIZATION) OR (GENETIC (W) (VACCI-
        NE OR VACCINATION)) OR (DNA-BASED (W) (VACCINE OR VACCINATION-
        )) OR (DNA (W) (VACCINE OR VACCINATION)) OR (GENE (W) THERAPY-
        )))
S7      9   RD (unique items)
S8      7   S7 NOT PD>030218
S9      0   (TATA (W) BOX) AND (INITIATION OR INITIATE) AND (TFIIB OR -
        (TRANSCRIPTION (W) FACTOR (W) IIB)) AND (UPSTREAM (W) REGULAT-
        ORY) AND ((DOWNSTREAM (W) REGULATORY) OR (DOWNSTREAM (W) PROM-
        OTER (W) (ELEMENT OR SITE OR REGION)))
? s s6 and ((Tata (w) box) and (initiation or initiate))
        19  S6
        58187 TATA
        250744 BOX
        31533 TATA(W)BOX
        638255 INITIATION
        151672 INITIATE
S10     0   S6 AND ((TATA (W) BOX) AND (INITIATION OR INITIATE))
? s s2 and ((Tata (w) box) and (initiation or initiate))
        25  S2
        58187 TATA
        250744 BOX
        31533 TATA(W)BOX
        638255 INITIATION
        151672 INITIATE
S11     0   S2 AND ((TATA (W) BOX) AND (INITIATION OR INITIATE))
? s ((Tata (w) box) and (initiation or initiate))
        58187 TATA
        250744 BOX
        31533 TATA(W)BOX
        638255 INITIATION
        151672 INITIATE
S12     9611 ((TATA (W) BOX) AND (INITIATION OR INITIATE))
? s s12 and (((synthesized or synthetic or artificial or optimized or
optimize) (w) (promoter or enhancer)))
        9611 S12
        804188 SYNTHESIZED
        1166292 SYNTHETIC
        1033333 ARTIFICIAL
        237542 OPTIMIZED
        131399 OPTIMIZE
        778601 PROMOTER
        172231 ENHANCER
        1737 (((SYNTHESIZED OR SYNTHETIC) OR ARTIFICIAL) OR
        (OPTIMIZED) OR OPTIMIZE) (W) (PROMOTER OR ENHANCER)
S13     52  S12 AND (((SYNTHESIZED OR SYNTHETIC OR ARTIFICIAL OR
        OPTIMIZED OR OPTIMIZE) (W) (PROMOTER OR ENHANCER)))
? s s13 and (((genetic (w) immunization) or (genetic (w) (vaccine or
vaccination)) or (DNA-based (w) (vaccine or vaccination)) or (DNA (w) (vaccine
or vaccination)) or (gene (w) therapy)))
Processing

```

Processed 10 of 29 files ...

Processing

Completed processing all files

```

      52  S13
3677542  GENETIC
394595   IMMUNIZATION
      3222 GENETIC(W)IMMUNIZATION
3677542  GENETIC
559059   VACCINE
362892   VACCINATION
      2586 GENETIC(W) (VACCINE OR VACCINATION)
      700  DNA-BASED
559059   VACCINE
362892   VACCINATION
      0    DNA-BASED(W) (VACCINE OR VACCINATION)
4834543  DNA
559059   VACCINE
362892   VACCINATION
      21780 DNA(W) (VACCINE OR VACCINATION)

5991666  GENE
8269902  THERAPY
      232644 GENE(W)THERAPY
S14      1  S13 AND (((GENETIC (W) IMMUNIZATION) OR (GENETIC (W)
              (VACCINE OR VACCINATION)) OR (DNA-BASED (W) (VACCINE OR
              VACCINATION)) OR (DNA (W) (VACCINE OR VACCINATION)) OR
              (GENE (W) THERAPY)))
```

? t s14/medium,k

14/K/1 (Item 1 from file: 73)

DIALOG(R)File 73:EMBASE

(c) 2006 Elsevier Science B.V. All rts. reserv.

11887912 EMBASE No: 2002459856

A Renilla luciferase-Aequorea GFP (ruc-gfp) fusion gene construct permits real-time detection of promoter activation by exogenously administered mifepristone in vivo

Yu Y.A.; Szalay A.A.

A.A. Szalay, Department of Biochemistry, Loma Linda Univ. School of Medicine, Loma Linda, CA 92350 United States

AUTHOR EMAIL: aszalay@som.llu.edu

Molecular Genetics and Genomics (MOL. GENET. GENOMICS) (Germany) 2002, 268/2 (169-178)

CODEN: MGGOA ISSN: 1617-4615

DOCUMENT TYPE: Journal ; Article

LANGUAGE: ENGLISH SUMMARY LANGUAGE: ENGLISH

NUMBER OF REFERENCES: 22

...domain and the activation domain of the herpes simplex virus protein VP16, and (3) a **synthetic promoter**, consisting of a series of GAL4 recognition sequences upstream of the adenovirus major late E1B **TATA box**, linked to a gene construct (ruc-gfp) encoding a Renilla luciferase-Aequorea green fluorescent protein...

...at specific stages of animal development. The method should also be of general use in **gene therapy**, since it permits simultaneous monitoring of the expression levels of light-emitting proteins and therapeutic...

MEDICAL DESCRIPTORS:

*promoter region; *gene construct; *transcription **initiation**

fusion gene; signal detection; transgene; gene expression; yeast; DNA

binding; **TATA box**; videorecording; microscope; enzyme analysis; genetic

```

transfection; leg muscle; nude mouse; injection; liver; cell
transplantation; plasmid...
? s ((Tata (w) box) and (initiation or initiate) and (TFIIB or (transcription
(w) factor (w) IIB)))
    58187 TATA
    250744 BOX
    31533 TATA(W) BOX
    638255 INITIATION
    151672 INITIATE
    4630 TFIIB
    1556031 TRANSCRIPTION
    5472768 FACTOR
    78310 IIB
    811 TRANSCRIPTION(W) FACTOR(W) IIB
S15 708 ((TATA (W) BOX) AND (INITIATION OR INITIATE) AND (TFIIB
OR (TRANSCRIPTION (W) FACTOR (W) IIB)))
? s s15 and (((synthesized or synthetic or engineered) and (optimized or
optimize))(s) (promoter or enhancer)))
    708 S15
    804188 SYNTHESIZED
    1166292 SYNTHETIC
    144724 ENGINEERED
    237542 OPTIMIZED
    131399 OPTIMIZE
    778601 PROMOTER
    172231 ENHANCER
    770 (((SYNTHESIZED OR SYNTHETIC) OR ENGINEERED) AND
(OPTIMIZED OR OPTIMIZE))(S) (PROMOTER OR ENHANCER)
S16 0 S15 AND (((SYNTHESIZED OR SYNTHETIC OR ENGINEERED) AND
(OPTIMIZED OR OPTIMIZE))(S) (PROMOTER OR ENHANCER)))
? s s15 and (((synthesized or synthetic or artificial or optimized or
optimize) (w) (promoter or enhancer)))
    708 S15
    804188 SYNTHESIZED
    1166292 SYNTHETIC
    1033333 ARTIFICIAL
    237542 OPTIMIZED
    131399 OPTIMIZE
    778601 PROMOTER
    172231 ENHANCER
    1737 (((((SYNTHESIZED OR SYNTHETIC) OR ARTIFICIAL) OR
OPTIMIZED) OR OPTIMIZE) (W) (PROMOTER OR ENHANCER)
S17 0 S15 AND (((SYNTHESIZED OR SYNTHETIC OR ARTIFICIAL OR
OPTIMIZED OR OPTIMIZE) (W) (PROMOTER OR ENHANCER)))
? s (((((interferon (w) regulatory (w) factor) or irf) (w) binding (w)
(element or site or region)) or (((interferon (w) regulatory (w) factor) or
irf) (w) (element or site or region))) or IRF or IRF-E or IRF-1 or IRF1 or
IRF2 or IRF-2 or (interferon (w) regulatory (w) factor)))
Processing
Processed 10 of 29 files ...
Processing
Processed 20 of 29 files ...
Completed_processing all files
    607811 INTERFERON
    937737 REGULATORY
    5472768 FACTOR
    8266 INTERFERON(W) REGULATORY(W) FACTOR
    10899 IRF
    4089834 BINDING
    2224532 ELEMENT
    3158871 SITE

```

```

5530878 REGION
100 (INTERFERON(W)REGULATORY(W)FACTOR OR
    IRF) (W) BINDING(W) ((ELEMENT OR SITE) OR REGION)
607811 INTERFERON
937737 REGULATORY
5472768 FACTOR
8266 INTERFERON(W)REGULATORY(W)FACTOR
10899 IRF
2224532 ELEMENT
3158871 SITE
5530878 REGION
136 (INTERFERON(W)REGULATORY(W)FACTOR OR IRF) (W) ((ELEMENT OR
    SITE) OR REGION)
10899 IRF
4 IRF-E
838 IRF-1
1443 IRF1
412 IRF2
134 IRF-2
607811 INTERFERON
937737 REGULATORY
5472768 FACTOR
8266 INTERFERON(W)REGULATORY(W)FACTOR
S18 14195 (((((INTERFERON (W) REGULATORY (W) FACTOR) OR IRF) (W)
    BINDING (W) (ELEMENT OR SITE OR REGION)) OR
    (((((INTERFERON (W) REGULATORY (W) FACTOR) OR IRF) (W)
    (ELEMENT OR SITE OR REGION))) OR IRF OR IRF-E OR IRF-1
    OR IRF1 OR IRF2 OR IRF-2 OR (INTERFERON (W) REGULATORY
    (W) FACTOR)))
? s s18 and (((synthesized or synthetic or artificial or optimized or
optimize) (w) (promoter or enhancer)))
14195 S18
804188 SYNTHESIZED
1166292 SYNTHETIC
1033333 ARTIFICIAL
237542 OPTIMIZED
131399 OPTIMIZE
778601 PROMOTER
172231 ENHANCER
1737 (((SYNTHESIZED OR SYNTHETIC) OR ARTIFICIAL) OR
    OPTIMIZED) OR OPTIMIZE) (W) (PROMOTER OR ENHANCER)
S19 8 S18 AND (((SYNTHESIZED OR SYNTHETIC OR ARTIFICIAL OR
    OPTIMIZED OR OPTIMIZE) (W) (PROMOTER OR ENHANCER)))
? rd

```

>>>Duplicate detection is not supported for File 391.

>>>Records from unsupported files will be retained in the RD set.

```

S20 5 RD (unique items)
? s s20 and ((Tata (w) box) and (initiation or initiate) and (TFIIB or
(transcription (w) factor (w) IIB)))

```

```

5 S20
58187 TATA
250744 BOX
31533 TATA(W)BOX
638255 INITIATION
151672 INITIATE
4630 TFIIB
1556031 TRANSCRIPTION
5472768 FACTOR
78310 IIB

```

```

      811 TRANSCRIPTION(W) FACTOR(W) IIB
S21      0 S20 AND ((TATA (W) BOX) AND (INITIATION OR INITIATE) AND
          (TFIIB OR (TRANSCRIPTION (W) FACTOR (W) IIB)))
? s s2 and (sp1 or sp-1 or irf or IRF-1 or IRF-e or IRF-2 or (interferon (w)
regulatory (w) factor) or cbp or (Cat (w) binding (w) protein) or AP-1 or AP1
or (activation (w) protein) or C-jun or NFkB or (NFKappaB) or CREB/ATF or NF1
or NF-1)
>>>Term "ATF" is not defined in one or more files
Processing
Sending Break...
?s s2 and (sp1 or sp-1 or irf or IRF-1 or IRF-e or IRF-2 or (interferon (w)
regulatory (w) factor) or cbp or (Cat (w) binding (w) protein) or AP-1 or AP1
or (activation (w) protein) or C-jun or NFkB or (NFKappaB) or CREB or ATF or
NF1 or NF-1)
Processing
Processed 10 of 29 files ...
Processing
Processed 20 of 29 files ...
Completed processing all files
      25 S2
     44432 SP1
      410 SP-1
    10899 IRF
      838 IRF-1
        4 IRF-E
      134 IRF-2
    607811 INTERFERON
    937737 REGULATORY
    5472768 FACTOR
      8266 INTERFERON(W) REGULATORY(W) FACTOR
    15892 CBP
    900711 CAT
    4089834 BINDING
    9053135 PROTEIN
        17 CAT(W) BINDING(W) PROTEIN
      7437 AP-1
    10621 AP1
    3037655 ACTIVATION
    9053135 PROTEIN
    15939 ACTIVATION(W) PROTEIN
    11343 C-JUN
      3133 NFKB
      9517 NFKAPPAB
     34742 CREB
     11756 ATF
     11299 NF1
      181 NF-1
S22      1 S2 AND (SP1 OR SP-1 OR IRF OR IRF-1 OR IRF-E OR IRF-2 OR
          (INTERFERON (W) REGULATORY (W) FACTOR) OR CBP OR (CAT (W)
          BINDING (W) PROTEIN) OR AP-1 OR AP1 OR (ACTIVATION (W)
          PROTEIN) OR C-JUN OR NFKB OR (NFKAPPAB) OR CREB OR ATF OR
          NF1 OR NF-1)

? t s22/free

```

22/8/1 (Item 1 from file: 357)
 0350206 DBR Accession No.: 2004-22498
New nucleic acid segment comprises SP72 synthetic promoter /enhancer,
useful as a vaccine for genetic immunization or for gene therapy
for treating or preventing cancers, infectious diseases, or
inflammatory diseases - construction of a nucleic acid vaccine
comprising the SP72 promoter useful for disease prevention and gene

therapy 2004
 ? s s2 and (sp1 or sp-1 or irf or IRF-1 or IRF-e or IRF-2 or (interferon (w) regulatory (w) factor) or cbp or (Cat (w) binding (w) protein) or AP-1 or AP1 or (activation (w) protein) or NFkB or (NFKappaB))
 Processing
 Processed 10 of 29 files ...
 Processing
 Completed processing all files

25	S2
44432	SP1
410	SP-1
10899	IRF
838	IRF-1
4	IRF-E
134	IRF-2
607811	INTERFERON
937737	REGULATORY
5472768	FACTOR
8266	INTERFERON (W) REGULATORY (W) FACTOR
15892	CBP
900711	CAT
4089834	BINDING
9053135	PROTEIN
17	CAT (W) BINDING (W) PROTEIN
7437	AP-1
10621	AP1
3037655	ACTIVATION
9053135	PROTEIN
15939	ACTIVATION (W) PROTEIN
3133	NFKB
9517	NFKAPPAB

S23 1 S2 AND (SP1 OR SP-1 OR IRF OR IRF-1 OR IRF-E OR IRF-2 OR (INTERFERON (W) REGULATORY (W) FACTOR) OR CBP OR (CAT (W) BINDING (W) PROTEIN) OR AP-1 OR AP1 OR (ACTIVATION (W) PROTEIN) OR NFKB OR (NFKAPPAB))

? t s23/free

23/8/1 (Item 1 from file: 357)
 0350206 DBR Accession No.: 2004-22498
New nucleic acid segment comprises SP72 synthetic promoter /enhancer, useful as a vaccine for genetic immunization or for gene therapy for treating or preventing cancers, infectious diseases, or inflammatory diseases - construction of a nucleic acid vaccine comprising the SP72 promoter useful for disease prevention and gene therapy 2004

? s ((synthesized or synthetic or artificial or engineered or optimized or optimize) (w) (promoter)) and (spacer or (spacer (w) region))

804188	SYNTHESIZED
1166292	SYNTHETIC
1033333	ARTIFICIAL
144724	ENGINEERED
237542	OPTIMIZED
131399	OPTIMIZE
778601	PROMOTER
1655	(((SYNTHESIZED OR SYNTHETIC) OR ARTIFICIAL) OR ENGINEERED) OR OPTIMIZED) OR OPTIMIZE) (W) PROMOTER
96622	SPACER
96622	SPACER
5530878	REGION
13344	SPACER (W) REGION

S24 36 ((SYNTHESIZED OR SYNTHETIC OR ARTIFICIAL OR ENGINEERED OR

```

                OPTIMIZED OR OPTIMIZE) (W) (PROMOTER )) AND (SPACER OR
                (SPACER (W) REGION) )
? s s24 and enhancer
      36 S24
    172231 ENHANCER
S25      2 S24 AND ENHANCER
? rd

>>>Duplicate detection is not supported for File 391.

>>>Records from unsupported files will be retained in the RD set.
      S26      2 RD (unique items)
? s s26 and ((Tata (w) box) and (initiation or initiate) and (TFIIB or
(transcription (w) factor (w) IIB)))
      2 S26
    58187 TATA
    250744 BOX
    31533 TATA(W)BOX
    638255 INITIATION
    151672 INITIATE
    4630 TFIIB
    1556031 TRANSCRIPTION
    5472768 FACTOR
    78310 IIB
    811 TRANSCRIPTION(W)FACTOR(W)IIB
S27      0 S26 AND ((TATA (W) BOX) AND (INITIATION OR INITIATE) AND
(TFIIB OR (TRANSCRIPTION (W) FACTOR (W) IIB)))
? s ((genetic (w) immunization (w) vector) or (genetic (w) immunization)) and
(HIV adj gp120)
    3677542 GENETIC
    394595 IMMUNIZATION
    865288 VECTOR
    22 GENETIC(W)IMMUNIZATION(W)VECTOR
    3677542 GENETIC
    394595 IMMUNIZATION
    3222 GENETIC(W)IMMUNIZATION
    0 HIV ADJ GP120
S28      0 ((GENETIC (W) IMMUNIZATION (W) VECTOR) OR (GENETIC (W)
IMMUNIZATION)) AND (HIV ADJ GP120)
? s ((genetic (w) immunization (w) vector) or (genetic (w) immunization)) and
(HIV (w) gp120)
    3677542 GENETIC
    394595 IMMUNIZATION
    865288 VECTOR
    22 GENETIC(W)IMMUNIZATION(W)VECTOR
    3677542 GENETIC
    394595 IMMUNIZATION
    3222 GENETIC(W)IMMUNIZATION
    860728 HIV
    37540 GP120
    2652 HIV(W)GP120
S29      9 ((GENETIC (W) IMMUNIZATION (W) VECTOR) OR (GENETIC (W)
IMMUNIZATION)) AND (HIV (W) GP120)
? rd

>>>Duplicate detection is not supported for File 391.

>>>Records from unsupported files will be retained in the RD set.
      S30      5 RD (unique items)
? s s30 and ((synthesized or synthetic or artificial or engineered or
optimized or optimize) (w) (promoter )) )

```

>>>Unmatched parentheses

? s s30 and ((synthesized or synthetic or artificial or engineered or optimized or optimize) (w) (promoter))

5 S30
804188 SYNTHESIZED
1166292 SYNTHETIC
1033333 ARTIFICIAL
144724 ENGINEERED
237542 OPTIMIZED
131399 OPTIMIZE
778601 PROMOTER
1655 (((((SYNTHESIZED OR SYNTHETIC) OR ARTIFICIAL) OR
ENGINEERED) OR OPTIMIZED) OR OPTIMIZE) (W) PROMOTER
S31 1 S30 AND ((SYNTHESIZED OR SYNTHETIC OR ARTIFICIAL OR
ENGINEERED OR OPTIMIZED OR OPTIMIZE) (W) (PROMOTER))

? t s31/free

31/8/1 (Item 1 from file: 357)

0350206 DBR Accession No.: 2004-22498

New nucleic acid segment comprises SP72 synthetic promoter /enhancer,
useful as a vaccine for genetic immunization or for gene therapy
for treating or preventing cancers, infectious diseases, or
inflammatory diseases - construction of a nucleic acid vaccine
comprising the SP72 promoter useful for disease prevention and gene
therapy 2004

? t s29/free/all

29/8/1 (Item 1 from file: 5)

0010308751 BIOSIS NO.: 199698776584

Induction of cytotoxic T lymphocytes and antitumor immunity with DNA
vaccines expressing single T cell epitopes
1996

29/8/2 (Item 1 from file: 24)

DIALOG(R) File 24:(c) 2006 CSA. All rts. reserv.

0001653365 IP ACCESSION NO: 3960334

Induction of cytotoxic T lymphocytes and antitumor immunity with DNA
vaccines expressing single T cell epitopes
PUBLICATION DATE: 1996

DESCRIPTORS: lymphocytes T; DNA; vaccines; killer cells; tumors

IDENTIFIERS: mice

SUBJ CATG: 06818, Cancer immunotherapy; 33365, Vaccines (other)

29/8/3 (Item 1 from file: 34)

DIALOG(R) File 34:(c) 2006 Inst for Sci Info. All rts. reserv.

06013071 Genuine Article#: XP310 Number of References: 42

Title: Comparison of nucleic acid and protein immunization for induction of
antibodies specific for HIV-1 gp120 (ABSTRACT AVAILABLE)

Publication date: 19970800

Journal Subject Category: IMMUNOLOGY

Descriptors--Author Keywords: DNA vaccination ; vaccine ; HIV gp120
IIIB ; IgG subclasses ; AIDS

Identifiers--Key Word Plus(R): IMMUNODEFICIENCY-VIRUS TYPE-1; N-LINKED
GLYCANS; IMMUNE-RESPONSES; MONOCLONAL-ANTIBODIES; ENVELOPE
GLYCOPROTEIN; V3 LOOP; BINDING; VACCINE; MICE; EXPRESSION

Research Fronts: 95-4860 002 (DNA VACCINES; **GENETIC IMMUNIZATION** ;
HEPATITIS-B VACCINATION; HUMORAL IMMUNE-RESPONSES)

29/8/4 (Item 2 from file: 34)

DIALOG(R)File 34:(c) 2006 Inst for Sci Info. All rts. reserv.

05949207 Genuine Article#: XJ336 Number of References: 12

Title: Anti-HIV env immunities elicited by nucleic acid vaccines (ABSTRACT AVAILABLE)

Publication date: 19970600

Journal Subject Category: IMMUNOLOGY

Descriptors--Author Keywords: DNA vaccines ; HIV ; **gp120** ; gp160 ;
cytotoxic T lymphocyte (CTL) ; helper T cells

Identifiers--KeyWord Plus(R): IMMUNODEFICIENCY-VIRUS; PROTECTIVE IMMUNITY;
INFLUENZA-VIRUS; INJECTION; RESPONSES

Research Fronts: 95-4860 001 (DNA VACCINES; **GENETIC IMMUNIZATION** ;
HEPATITIS-B VACCINATION; HUMORAL IMMUNE-RESPONSES)

95-7458 001 (FELINE IMMUNODEFICIENCY VIRUS; T-CELL REPERTOIRE DURING
ACUTE HIV SYNDROME; ATTENUATED VACCINE FOR AIDS; RHESUS MACAQUES)

29/8/5 (Item 3 from file: 34)

DIALOG(R)File 34:(c) 2006 Inst for Sci Info. All rts. reserv.

04685133 Genuine Article#: UB155 Number of References: 43

**Title: INDUCTION OF CYTOTOXIC T-LYMPHOCYTES AND ANTITUMOR IMMUNITY WITH DNA
VACCINES EXPRESSING SINGLE T-CELL EPITOPES** (Abstract Available)

Journal Subject Category: IMMUNOLOGY

Identifiers--KeyWords Plus: IMMUNODEFICIENCY-VIRUS TYPE-1; **GENETIC
IMMUNIZATION** ; PEPTIDE; PROTECTION; ANTIGEN; INVIVO; RECOGNITION;
INFECTION; RESPONSES; PROTEIN

Research Fronts: 94-8400 002 (DIRECT DNA INJECTION; VACCINE DELIVERY;
IN-VIVO GENE-TRANSFER; PROTECTIVE IMMUNITY; NUCLEIC-ACID IMMUNIZATION;
SKELETAL-MUSCLE CELLS; RABIES VIRUS)

94-0428 001 (MEMORY CD4(+) T-CELL ADHESION; MULTIPLE SUBSETS;

DIFFERENTIAL EXPRESSION; CD45RA(+) PERIPHERAL-BLOOD LYMPHOCYTES)

94-1576 001 (MAJOR HISTOCOMPATIBILITY COMPLEX CLASS-I GENES; PEPTIDE
PRESENTATION; IMMUNE RECOGNITION; ANCHOR RESIDUES)

94-4000 001 (P53 GENE; NONSMALL CELL LUNG-CANCER; FREQUENT EXPRESSED
TRANSITION MUTATIONS)

29/8/6 (Item 1 from file: 73)

06432505 EMBASE No: 1996094923

**Induction of cytotoxic T lymphocytes and antitumor immunity with DNA
vaccines expressing single T cell epitopes**
1996

29/8/7 (Item 1 from file: 135)

DIALOG(R)File 135:(c) 2006 NewsRx. All rts. reserv.

0000012533 (USE FORMAT 7 OR 9 FOR FULLTEXT)

**"Induction of Cytotoxic T Lymphocytes and Antitumor Immunity with DNA
Vaccines Expressing Single T Cell Epitopes."**

WORD COUNT: 243

May 6, 1996 (19960506)

DESCRIPTORS: news

SUBJECT HEADING: DNA Vaccines

29/8/8 (Item 1 from file: 155)

DIALOG(R) File 155:(c) format only 2006 Dialog. All rts. reserv.

10813739 PMID: 8786293

Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes.

Apr 1 1996

Tags: Female

Descriptors: *DNA--genetics--GE; *DNA--immunology--IM; *Neoplasms, Experimental--immunology--IM; *T-Lymphocytes, Cytotoxic--immunology--IM; *Vaccines, Synthetic--pharmacology--PD; Adenoviridae--genetics--GE; Animals; Base Sequence; Endoplasmic Reticulum--immunology--IM; Epitopes--genetics--GE; Genes, p53; HIV Envelope Protein gp120--genetics--GE; Humans; Immunization; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Neoplasms, Experimental--prevention and control--PC; Oligodeoxyribonucleotides--genetics--GE; Vaccines, Synthetic--genetics--GE

CAS Registry No.: 0 (Epitopes); 0 (HIV Envelope Protein gp120); 0 (Oligodeoxyribonucleotides); 0 (Vaccines, Synthetic); 9007-49-2 (DNA)

29/8/9 (Item 1 from file: 357)

0350206 DBR Accession No.: 2004-22498

New nucleic acid segment comprises SP72 synthetic promoter/enhancer, useful as a vaccine for genetic immunization or for gene therapy for treating or preventing cancers, infectious diseases, or inflammatory diseases - construction of a nucleic acid vaccine comprising the SP72 promoter useful for disease prevention and gene therapy 2004

? ds

Set	Items	Description
S1	234	((SYNTHESIZED OR SYNTHETIC OR ARTIFICIAL OR OPTIMIZED OR - OPTIMIZE) (W) (PROMOTER AND ENHANCER))
S2	25	S1 AND (((GENETIC (W) IMMUNIZATION) OR (GENETIC (W) (VACCI- NE OR VACCINATION)) OR (DNA-BASED (W) (VACCINE OR VACCINATION-)) OR (DNA (W) (VACCINE OR VACCINATION)) OR (GENE (W) THERAPY-)))
S3	9	S2 AND ((OPTIMIZED OR OPTIMIZE) (W) (PROMOTER AND ENHANCER-))
S4	2	RD (unique items)
S5	55	((SYNTHESIZED OR SYNTHETIC OR ENGINEERED) AND (OPTIMIZED - OR OPTIMIZE)) (S) (PROMOTER AND ENHANCER)
S6	19	S5 AND (((GENETIC (W) IMMUNIZATION) OR (GENETIC (W) (VACCI- NE OR VACCINATION)) OR (DNA-BASED (W) (VACCINE OR VACCINATION-)) OR (DNA (W) (VACCINE OR VACCINATION)) OR (GENE (W) THERAPY-)))
S7	9	RD (unique items)
S8	7	S7 NOT PD>030218
S9	0	(TATA (W) BOX) AND (INITIATION OR INITIATE) AND (TFIIB OR - (TRANSCRIPTION (W) FACTOR (W) IIB)) AND (UPSTREAM (W) REGULAT- ORY) AND ((DOWNSTREAM (W) REGULATORY) OR (DOWNSTREAM (W) PROM- OTER (W) (ELEMENT OR SITE OR REGION)))
S10	0	S6 AND ((TATA (W) BOX) AND (INITIATION OR INITIATE))
S11	0	S2 AND ((TATA (W) BOX) AND (INITIATION OR INITIATE))
S12	9611	((TATA (W) BOX) AND (INITIATION OR INITIATE))
S13	52	S12 AND ((SYNTHESIZED OR SYNTHETIC OR ARTIFICIAL OR OPTI- MIZED OR OPTIMIZE) (W) (PROMOTER OR ENHANCER))
S14	1	S13 AND (((GENETIC (W) IMMUNIZATION) OR (GENETIC (W) (VACC-

INE OR VACCINATION)) OR (DNA-BASED (W) (VACCINE OR VACCINATION)) OR (DNA (W) (VACCINE OR VACCINATION)) OR (GENE (W) THERAPY)))

S15 708 ((TATA (W) BOX) AND (INITIATION OR INITIATE) AND (TFIIB OR (TRANSCRIPTION (W) FACTOR (W) IIB)))

S16 0 S15 AND (((SYNTHESIZED OR SYNTHETIC OR ENGINEERED) AND (OPTIMIZED OR OPTIMIZE)) (S) (PROMOTER OR ENHANCER)))

S17 0 S15 AND (((SYNTHESIZED OR SYNTHETIC OR ARTIFICIAL OR OPTIMIZED OR OPTIMIZE) (W) (PROMOTER OR ENHANCER)))

S18 14195 (((((INTERFERON (W) REGULATORY (W) FACTOR) OR IRF) (W) BINDING (W) (ELEMENT OR SITE OR REGION)) OR (((INTERFERON (W) - REGULATORY (W) FACTOR) OR IRF) (W) (ELEMENT OR SITE OR REGION))) OR IRF OR IRF-E OR IRF-1 OR IRF1 OR IRF2 OR IRF-2 OR (INTERFERON (W) R

S19 8 S18 AND (((SYNTHESIZED OR SYNTHETIC OR ARTIFICIAL OR OPTIMIZED OR OPTIMIZE) (W) (PROMOTER OR ENHANCER)))

S20 5 RD (unique items)

S21 0 S20 AND ((TATA (W) BOX) AND (INITIATION OR INITIATE) AND (-TFIIB OR (TRANSCRIPTION (W) FACTOR (W) IIB)))

S22 1 S2 AND (SP1 OR SP-1 OR IRF OR IRF-1 OR IRF-E OR IRF-2 OR (-INTERFERON (W) REGULATORY (W) FACTOR) OR CBP OR (CAT (W) BINDING (W) PROTEIN) OR AP-1 OR AP1 OR (ACTIVATION (W) PROTEIN) OR C-JUN OR NFKB OR (NFKAPPAB) OR CREB OR ATF OR NF1 OR NF-1)

S23 1 S2 AND (SP1 OR SP-1 OR IRF OR IRF-1 OR IRF-E OR IRF-2 OR (-INTERFERON (W) REGULATORY (W) FACTOR) OR CBP OR (CAT (W) BINDING (W) PROTEIN) OR AP-1 OR AP1 OR (ACTIVATION (W) PROTEIN) OR NFKB OR (NFKAPPAB))

S24 36 (((SYNTHESIZED OR SYNTHETIC OR ARTIFICIAL OR ENGINEERED OR -OPTIMIZED OR OPTIMIZE) (W) (PROMOTER)) AND (SPACER OR (SPACER (W) REGION))

S25 2 S24 AND ENHANCER

S26 2 RD (unique items)

S27 0 S26 AND ((TATA (W) BOX) AND (INITIATION OR INITIATE) AND (-TFIIB OR (TRANSCRIPTION (W) FACTOR (W) IIB)))

S28 0 ((GENETIC (W) IMMUNIZATION (W) VECTOR) OR (GENETIC (W) IMMUNIZATION)) AND (HIV ADJ GP120)

S29 9 ((GENETIC (W) IMMUNIZATION (W) VECTOR) OR (GENETIC (W) IMMUNIZATION)) AND (HIV (W) GP120)

S30 5 RD (unique items)

S31 1 S30 AND (((SYNTHESIZED OR SYNTHETIC OR ARTIFICIAL OR ENGINEERED OR OPTIMIZED OR OPTIMIZE) (W) (PROMOTER))

? s (Tata (w) box) and (initiation or initiate) and (TFIIB or (transcription (w) factor (w) IIB)) and (upstream (s) regulatory) and ((downstream (s) regulatory) or (downstream (s) promoter (w) (element or site or region)))

Processing

Processed 10 of 29 files ...

Completed processing all files

58187 TATA
250744 BOX
31533 TATA(W)BOX
638255 INITIATION
151672 INITIATE
4630 TFIIB
1556031 TRANSCRIPTION
5472768 FACTOR
78310 IIB
811 TRANSCRIPTION(W) FACTOR(W) IIB
311345 UPSTREAM
937737 REGULATORY
48504 UPSTREAM(S) REGULATORY
334581 DOWNSTREAM

937737 REGULATORY
 23389 DOWNSTREAM(S) REGULATORY
 334581 DOWNSTREAM
 778601 PROMOTER
 2224532 ELEMENT
 3158871 SITE
 5530878 REGION
 6246 DOWNSTREAM(S) PROMOTER(W) ((ELEMENT OR SITE) OR REGION)
 S32 5 (TATA (W) BOX) AND (INITIATION OR INITIATE) AND (TFIIB OR
 (TRANSCRIPTION (W) FACTOR (W) IIB)) AND (UPSTREAM (S)
 REGULATORY) AND ((DOWNSTREAM (S) REGULATORY) OR
 (DOWNSTREAM (S) PROMOTER (W) (ELEMENT OR SITE OR
 REGION)))

? rd

>>>Duplicate detection is not supported for File 391.

>>>Records from unsupported files will be retained in the RD set.

S33 5 RD (unique items)
 ? t s33/free/all

33/8/1 (Item 1 from file: 34)

DIALOG(R)File 34:(c) 2006 Inst for Sci Info. All rts. reserv.

03487179 Genuine Article#: PH031 Number of References: 57

**Title: 2 ALTERNATIVE PATHWAYS OF TRANSCRIPTION INITIATION IN THE YEAST
 NEGATIVE REGULATORY GENE GAL80** (Abstract Available)

Journal Subject Category: BIOCHEMISTRY & MOLECULAR BIOLOGY

Identifiers--KeyWords Plus: TATA-LESS PROMOTER; RNA POLYMERASE-II;

SACCHAROMYCES-CEREVISIAE; MOLECULAR MECHANISMS; NUCLEOTIDE-SEQUENCE;
 CHROMATIN STRUCTURE; TFIID COMPLEX; HIS4 GENE; PROTEIN; ACTIVATOR

Research Fronts: 92-2833 002 (SACCHAROMYCES-CEREVISIAE RNA POLYMERASE-C
 (III); YEAST HOMOLOG; NUCLEAR GENE; MITOCHONDRIAL PROTEIN IMPORT)

92-3425 002 (RNA POLYMERASE-II TRANSCRIPTION; TATA-BINDING PROTEIN;
 BASAL PROMOTER FACTOR **TFIIB**)

92-4812 001 (PUTATIVE ANAEROBIC COPROPORPHYRINOGEN-III OXIDASE IN
 RHODOBACTER-SPHAEROIDES; TRANSCRIPTIONAL REGULATORY ELEMENT; FUNCTIONAL
 EXPRESSION)

92-6848 001 (TRANSCRIPTIONAL ACTIVATION DOMAIN; PROMOTER REGION;
 DNA-BINDING PROTEINS; NUCLEAR FACTORS; RNA POLYMERASE-II)

33/8/2 (Item 2 from file: 34)

DIALOG(R)File 34:(c) 2006 Inst for Sci Info. All rts. reserv.

03233975 Genuine Article#: NN510 Number of References: 55

**Title: RESTRICTION OF INTERFERON-GAMMA RESPONSIVENESS AND BASAL EXPRESSION
 OF THE MYELOID HUMAN FC-GAMMA-R1B GENE IS MEDIATED BY A FUNCTIONAL PU.1
 SITE AND A TRANSCRIPTION INITIATOR CONSENSUS** (Abstract Available)

Journal Subject Category: IMMUNOLOGY; MEDICINE, RESEARCH & EXPERIMENTAL

Identifiers--KeyWords Plus: DNA-BINDING PROTEINS; TYROSINE PHOSPHORYLATION;
 IFN-GAMMA; CYTOPLASMIC ACTIVATION; SIGNAL-TRANSDUCTION; RESPONSE
 ELEMENTS; NUCLEAR FACTOR; RECEPTOR GENE; GROWTH-FACTOR; PROMOTER

Research Fronts: 92-3425 001 (RNA POLYMERASE-II TRANSCRIPTION;
 TATA-BINDING PROTEIN; BASAL PROMOTER FACTOR **TFIIB**)

92-7069 001 (ETS GENE FAMILY; DNA-BINDING DOMAIN; DIRECT INTERACTION OF
 CREB PROTEIN)

33/8/3 (Item 1 from file: 35)

01614806 ORDER NO: AAD98-13362

**REGULATION OF GENE TRANSCRIPTION IN THE ARCHAEON HALOFERAX VOLCANII USING
THE HEAT SHOCK RESPONSE AS A MODEL SYSTEM**

Year: 1997

33/8/4 (Item 1 from file: 98)

DIALOG(R)File 98:(c) 2005 The HW Wilson Co. All rts. reserv.

03253325 H.W. WILSON RECORD NUMBER: BGSI96003325 (USE FORMAT 7 FOR
FULLTEXT)

Yeast transcriptional regulatory mechanisms.

WORD COUNT: 11208

DESCRIPTORS:

Fungal genetics; Transcription factors; Promoter region; Saccharomyces
'95 (19950000)

33/8/5 (Item 2 from file: 98)

DIALOG(R)File 98:(c) 2005 The HW Wilson Co. All rts. reserv.

03051103 H.W. WILSON RECORD NUMBER: BGSI95051103 (USE FORMAT 7 FOR
FULLTEXT)

**Development and application of herpes simplex virus vectors for human gene
therapy.**

WORD COUNT: 16710

DESCRIPTORS:

Herpes simplex virus; Promoter region; Gene therapy; Nervous system--
Diseases; Cancer--Therapy
'95 (19950000)
? t s33/medium,k/4

33/K/4 (Item 1 from file: 98)

DIALOG(R)File 98:General Sci Abs

(c) 2005 The HW Wilson Co. All rts. reserv.

03253325 H.W. WILSON RECORD NUMBER: BGSI96003325 (USE FORMAT 7 FOR
FULLTEXT)

Yeast transcriptional regulatory mechanisms.

Struhl, Kevin

Annual Review of Genetics (Annu Rev Genet) v. 29 ('95) p. 651-74

SPECIAL FEATURES: bibl ISSN: 0066-4197

LANGUAGE: English

COUNTRY OF PUBLICATION: United States

WORD COUNT: 11208

(USE FORMAT 7 FOR FULLTEXT)

TEXT:

PROMOTER ELEMENTS

Yeast Pol II promoters contain **upstream** (UAS), TATA, and initiator (Inr) elements whose properties have been reviewed previously (127). **Upstream** elements are short (10-30 bp), promoter-specific DNA sequences that are typically located 50 to 500 bp **upstream** of the **initiation** site. Yeast **upstream** elements are analogous, and in many cases homologous, to mammalian enhancer sequences. However, while yeast **upstream** elements function bidirectionally at variable distances **upstream** of the **initiation** site, they generally do not activate transcription when located

downstream . In general, **upstream** elements are recognized by DNA-binding proteins that determine the particular **regulatory** properties of a given promoter. However, approximately 20[percent] of yeast promoters contain homopolymeric dA:dT tracts that function as **upstream** elements by virtue of their intrinsic DNA structure, not by interacting with a specific DNA...

...protein (60).

Most yeast promoters contain TATA elements (consensus TATAAA) that are important for transcriptional **initiation** . Yeast TATA elements are located 40-120 bp upstream of the mRNA **initiation** sites; the precise distance is functionally unimportant. In contrast, TATA sequences in most other eukaryotes are invariably located 25-30 bp away from the **initiation** site. TATA elements are recognized by the TATA-binding protein (TBP), a component of the...

...have a relatively modest effect on the level of transcription.

Some yeast promoters contain negative **regulatory** elements, termed operators, that repress transcription. Operators resemble **upstream** elements in that they are protein-binding sites that function bidirectionally at variable distances **upstream** of TATA elements. Some operators can repress transcription when located **upstream** of **upstream** elements, but repression is generally much more efficient when the operator lies between the **upstream** and TATA element. However, the mating-type silencer efficiently represses transcription when located 2 kb **upstream** or **downstream** from the **initiation** sites.

GENERAL TRANSCRIPTION FACTORS

Biochemical analysis of yeast and mammalian proteins has led to a...

...mechanism by which it initiates transcription (15, 23). In yeast, the essential components for accurate **initiation** in vitro are Pol II, a 12-subunit enzyme (149), as well as general transcription factors TBP (53, 128), **TFIIB** (105), TFIIE (35), TFIIF (52), and TFIIH (36). TBP binds to the TATA element, **TFIIB** spans the region between the TATA element and mRNA **initiation** site, TFIIF interacts with Pol II and is important in recruiting Pol II to the...

...binding of TBP to the TATA element, is important but not absolutely required for accurate **initiation** in vitro (65, 72). In addition, TBP-associated factors (TAFs) that are part of the...
...can be considered as general transcription factors even though they are not required for accurate **initiation** in vitro.

In vitro, accurate **initiation** and the response to activators can occur with recombinant or highly purified general transcription factors...

...transcription factors suggests the possibility that much of transcription apparatus (other than TBP and perhaps **TFIIB**) is preassembled before being recruited to the promoter (72, 76).

Although this biochemical description of...

...surface of the saddle and the α helices are also oriented with respect to the **initiation** site. Amino acid changes at specific positions on the convex surface or α helices can specifically affect interactions with TFIIA (16, 123), **TFIIB** (70), and Spt3 (32). Thus, the orientation of TBP on the TATA element defines the...a less important (and perhaps no) role in constitutive Pol II transcription.

SELECTION OF MRNA INITIATION SITE BY TFIIB AND POL II

TFIIB and Pol II are the basal transcription factors that are primarily responsible for selecting the **initiation** site. As mentioned previously, *S. cerevisiae* differs from most other eukaryotic organisms in that the distance between the TATA element and **initiation** site is longer and more variable. In reconstituted transcription reactions using basic factors from *S. cerevisiae*, replacement of both **TFIIB** and Pol II by their *S. pombe* counterparts is necessary and sufficient to shift **initiation** to a site characteristic of that in *S. pombe* (87). In vivo, mutations affecting either **TFIIB** or the largest subunit of Pol II (Rpb1) can reduce **initiation** from the normal site while increasing **initiation** from more downstream sites (10, 106). Conversely, mutations affecting another Pol II subunit, Rpb9, shift **initiation** to more upstream sites (39, 58).

TFIIH CONNECTS POL II TRANSCRIPTION, DNA REPAIR, AND CELL...its precise composition remains to be clarified, the Pol II holoenzyme contains **TFIIF**, and perhaps **TFIIB** and **TFIIH**. TBP may weakly associate with the holoenzyme but is probably not a true...

...that interactions between activation domains and general factors that function after TBP recruitment (e.g. **TFIIB**, **TFIIF**, Pol II) can be bypassed for transcriptional activation. The hypothesis that activators stimulate TBP...domains might interact with proteins that associate with **TFIIA** or TBP (e.g. TAFs or **TFIIB**). Alternatively, acidic activation domains might directly cause, or indirectly lead to, alterations in chromatin structure...**REPRESSION**

REPRESSION BY INHIBITING THE FUNCTION OF ACTIVATORS

Given the complexities involved in the basic **initiation** and transcriptional activation processes, it follows that transcription can be repressed by a variety of...largest subunit of RNA polymerase II and affect transcription start site selection similarly to *sua7* (**TFIIB**) mutations. Mol. Cell. Biol. 14:226-37

11. Brazas RM, Stillman DJ. 1993. The *Swi5*...

...TATA-element utilization. Genes Dev. 8:525-37

23. Conaway RC, Conaway JW. 1993. General **initiation** factors for RNA polymerase II. Annu. Rev. Biochem. 62:161-90

24. Cormack BP, Strubin...

...Dever TE, Feng L, Wek RC, Cigan AM, Donahue TF, Hinnebusch AG. 1992. Phosphorylation of **initiation** factor 2a by protein kinase GCN2 mediates genespecific translational control of GCN4 in yeast. Cell...Flanagan PM, Kornberg RD, et al. 1994. Effects of activation-defective TBP mutations on transcription **initiation** in yeast. Nature 369:252-55

71. Kim Y, Geiger JH, Hahn S, Sigler PB. 1993. Crystal structure of a yeast TBP- **TATA** box complex. Nature 365:512-20

72. Kim Y-J, Bjorklund S, Li Y, Sayre MH...
...77:599-608

73. Klages N, Strubin M. 1995. Stimulation of RNA polymerase II transcription **initiation** by recruitment of TBP in vivo. Nature 374:822-23

74. Klein C, Struhl K...1333-35

87. Li Y, Flanagan PM, Tschochner H, Kornberg RD. 1994. RNA polymerase II **initiation** factor interactions and transcription start site selection. Science 263:805-7

88. Liao S-M...

...GAL11 protein mediates the transcriptional activation signal of two different transacting factors, GAL4 and general **regulatory** factor

1/repressor/activator site binding protein 1/translation **upstream** factor.
Proc. Natl. Acad. Sci. USA 87:5373-77

103. Oliviero S, Struhl K. 1991...

...DE, Hampsey M. 1992. The yeast SUA7 gene encodes a homolog of human transcription factor **TFIIB** and is required for normal start site selection in vivo. Cell 68:977-88

106...

...W-H, Na JG, Hampsey M. 1994. Characterization of sua7 mutations defines a domain of **TFIIB** involved in transcription start site selection in yeast. J. Biol. Chem. 269:30569-73

107...

? t s33/medium,k/3

33/K/3 (Item 1 from file: 35)

DIALOG(R) File 35:Dissertation Abs Online

(c) 2006 ProQuest Info&Learning. All rts. reserv.

01614806 ORDER NO: AAD98-13362

REGULATION OF GENE TRANSCRIPTION IN THE ARCHAEON HALOFERAX VOLCANII USING THE HEAT SHOCK RESPONSE AS A MODEL SYSTEM

Author: THOMPSON, DOROTHEA KATHLEEN

Degree: PH.D.

Year: 1997

Corporate Source/Institution: THE OHIO STATE UNIVERSITY (0168)

Source: VOLUME 58/10-B OF DISSERTATION ABSTRACTS INTERNATIONAL.

PAGE 5256. 205 PAGES

...possess a eucaryal-like basic transcription machinery, consisting of the TATA-binding protein (TBP), the **TFIIB** homolog (TFB), and RNA polymerase. How the archaeal preinitiation complex regulates the expression of diverse...

...heat-inducible cct (chaperonin-containing Tcp-1) family member gene. Transcriptional fusions of the cct1 **promoter region** with a yeast tRNA reporter gene were constructed to analyze the functional domains of this heat shock promoter. Deletion mutagenesis indicated that the \$5\backslash\text{sp}\backslash\text{prime}\$ boundary of the cct1 **regulatory** region mapped to position-37 relative to the transcription start. Alignment with the promoter regions...

...degree of sequence conservation in and immediately flanking the TATA motif of the putative core **promoter element**. Mutational analysis of conserved sequences demonstrated that transcription depends on sequence elements located **upstream** and **downstream** of the **TATA box**. These findings suggest that the **regulatory** mechanism controlling heat shock gene expression in Archaea differs significantly from the bacterial and eucaryal...

...\$5\backslash\text{sp}\backslash\text{prime}\$-TTTATA-3\$\backslash\text{sp}\backslash\text{prime}\$) centered at position-26 relative to the mapped **initiation** site. We demonstrated that a termination element located **downstream** of the transcription start site in the DNA leader region negatively modulates expression of this...

...study indicate that the heat-responsive TFB2 is likely a component in the heat shock **regulatory** response, they also suggest that additional factors are needed.

? ds

Set	Items	Description
S1	234	((SYNTHESIZED OR SYNTHETIC OR ARTIFICIAL OR OPTIMIZED OR -

OPTIMIZE) (W) (PROMOTER AND ENHANCER))

S2 25 S1 AND (((GENETIC (W) IMMUNIZATION) OR (GENETIC (W) (VACCI-
NE OR VACCINATION)) OR (DNA-BASED (W) (VACCINE OR VACCINATION-
)) OR (DNA (W) (VACCINE OR VACCINATION)) OR (GENE (W) THERAPY-
)))

S3 9 S2 AND ((OPTIMIZED OR OPTIMIZE) (W) (PROMOTER AND ENHANCER-
))

S4 2 RD (unique items)

S5 55 (((SYNTHESIZED OR SYNTHETIC OR ENGINEERED) AND (OPTIMIZED -
OR OPTIMIZE)) (S) (PROMOTER AND ENHANCER))

S6 19 S5 AND (((GENETIC (W) IMMUNIZATION) OR (GENETIC (W) (VACCI-
NE OR VACCINATION)) OR (DNA-BASED (W) (VACCINE OR VACCINATION-
)) OR (DNA (W) (VACCINE OR VACCINATION)) OR (GENE (W) THERAPY-
)))

S7 9 RD (unique items)

S8 7 S7 NOT PD>030218

S9 0 (TATA (W) BOX) AND (INITIATION OR INITIATE) AND (TFIIB OR -
(TRANSCRIPTION (W) FACTOR (W) IIB)) AND (UPSTREAM (W) REGULAT-
ORY) AND ((DOWNSTREAM (W) REGULATORY) OR (DOWNSTREAM (W) PROM-
OTER (W) (ELEMENT OR SITE OR REGION)))

S10 0 S6 AND ((TATA (W) BOX) AND (INITIATION OR INITIATE))

S11 0 S2 AND ((TATA (W) BOX) AND (INITIATION OR INITIATE))

S12 9611 ((TATA (W) BOX) AND (INITIATION OR INITIATE))

S13 52 S12 AND (((SYNTHESIZED OR SYNTHETIC OR ARTIFICIAL OR OPTI-
MIZED OR OPTIMIZE) (W) (PROMOTER OR ENHANCER)))

S14 1 S13 AND (((GENETIC (W) IMMUNIZATION) OR (GENETIC (W) (VACC-
INE OR VACCINATION)) OR (DNA-BASED (W) (VACCINE OR VACCINATIO-
N)) OR (DNA (W) (VACCINE OR VACCINATION)) OR (GENE (W) THERAP-
Y)))

S15 708 ((TATA (W) BOX) AND (INITIATION OR INITIATE) AND (TFIIB OR
(TRANSCRIPTION (W) FACTOR (W) IIB)))

S16 0 S15 AND (((SYNTHESIZED OR SYNTHETIC OR ENGINEERED) AND (O-
PTIMIZED OR OPTIMIZE)) (S) (PROMOTER OR ENHANCER)))

S17 0 S15 AND (((SYNTHESIZED OR SYNTHETIC OR ARTIFICIAL OR OPTI-
MIZED OR OPTIMIZE) (W) (PROMOTER OR ENHANCER)))

S18 14195 (((((INTERFERON (W) REGULATORY (W) FACTOR) OR IRF) (W) BIN-
DING (W) (ELEMENT OR SITE OR REGION)) OR (((INTERFERON (W) -
REGULATORY (W) FACTOR) OR IRF) (W) (ELEMENT OR SITE OR REGION-
))) OR IRF OR IRF-E OR IRF-1 OR IRF1 OR IRF2 OR IRF-2 OR (IN-
TERFERON (W) R

S19 8 S18 AND (((SYNTHESIZED OR SYNTHETIC OR ARTIFICIAL OR OPTI-
MIZED OR OPTIMIZE) (W) (PROMOTER OR ENHANCER)))

S20 5 RD (unique items)

S21 0 S20 AND ((TATA (W) BOX) AND (INITIATION OR INITIATE) AND (-
TFIIB OR (TRANSCRIPTION (W) FACTOR (W) IIB)))

S22 1 S2 AND (SP1 OR SP-1 OR IRF OR IRF-1 OR IRF-E OR IRF-2 OR (-
INTERFERON (W) REGULATORY (W) FACTOR) OR CBP OR (CAT (W) BIND-
ING (W) PROTEIN) OR AP-1 OR AP1 OR (ACTIVATION (W) PROTEIN) OR
C-JUN OR NFKB OR (NFKAPPAB) OR CREB OR ATF OR NF1 OR NF-1)

S23 1 S2 AND (SP1 OR SP-1 OR IRF OR IRF-1 OR IRF-E OR IRF-2 OR (-
INTERFERON (W) REGULATORY (W) FACTOR) OR CBP OR (CAT (W) BIND-
ING (W) PROTEIN) OR AP-1 OR AP1 OR (ACTIVATION (W) PROTEIN) OR
NFKB OR (NFKAPPAB))

S24 36 ((SYNTHESIZED OR SYNTHETIC OR ARTIFICIAL OR ENGINEERED OR -
OPTIMIZED OR OPTIMIZE) (W) (PROMOTER)) AND (SPACER OR (SPACER
(W) REGION))

S25 2 S24 AND ENHANCER

S26 2 RD (unique items)

S27 0 S26 AND ((TATA (W) BOX) AND (INITIATION OR INITIATE) AND (-
TFIIB OR (TRANSCRIPTION (W) FACTOR (W) IIB)))

S28 0 ((GENETIC (W) IMMUNIZATION (W) VECTOR) OR (GENETIC (W) IMM-

```

          UNIZATION)) AND (HIV ADJ GP120)
S29      9  ((GENETIC (W) IMMUNIZATION (W) VECTOR) OR (GENETIC (W) IMM-
          UNIZATION)) AND (HIV (W) GP120)
S30      5  RD (unique items)
S31      1  S30 AND ((SYNTHESIZED OR SYNTHETIC OR ARTIFICIAL OR ENGINE-
          ERED OR OPTIMIZED OR OPTIMIZE) (W) (PROMOTER ))
S32      5  (TATA (W) BOX) AND (INITIATION OR INITIATE) AND (TFIIB OR -
          (TRANSCRIPTION (W) FACTOR (W) IIB)) AND (UPSTREAM (S) REGULAT-
          ORY) AND ((DOWNSTREAM (S) REGULATORY) OR (DOWNSTREAM (S) PROM-
          OTER (W) (ELEMENT OR SITE OR REGION)))
S33      5  RD (unique items)

```

? save temp

Temp SearchSave "TA218796477" stored

? logoff

```

06apr06 10:44:59 User276741 Session D121.2
$29.69    5.032 DialUnits File5
          $0.00  6 Type(s) in Format  6
          $0.80  5 Type(s) in Format 95 (KWIC)
          $0.80  11 Types
$30.49    Estimated cost File5
          $10.00   1.613 DialUnits File24
          $0.00  1 Type(s) in Format  8
          $0.00  1 Types
$10.00    Estimated cost File24
          $1.46    0.236 DialUnits File28
$1.46     Estimated cost File28
          $105.72   4.505 DialUnits File34
          $0.00  5 Type(s) in Format  8
          $0.00  5 Types
$105.72   Estimated cost File34
          $2.26    0.552 DialUnits File35
          $0.00  1 Type(s) in Format  6
          $0.10  1 Type(s) in Format 95 (KWIC)
          $0.10  2 Types
$2.36     Estimated cost File35
          $2.07    0.290 DialUnits File40
$2.07     Estimated cost File40
          $1.36    0.219 DialUnits File41
$1.36     Estimated cost File41
          $4.96    1.078 DialUnits File50
$4.96     Estimated cost File50
          $1.31    0.350 DialUnits File65
$1.31     Estimated cost File65
          $16.05   1.824 DialUnits File71
$16.05    Estimated cost File71
          $60.46   5.398 DialUnits File73
          $6.20   2 Type(s) in Format  3
          $0.00  2 Type(s) in Format  6
          $6.20   4 Types
$66.66    Estimated cost File73
          $0.78    0.182 DialUnits File91
$0.78     Estimated cost File91
          $4.07    1.162 DialUnits File94
$4.07     Estimated cost File94
          $2.20    0.517 DialUnits File98
          $1.45    1 Type(s) in Format  3
          $0.00  2 Type(s) in Format  8
          $1.45   3 Types
$3.65     Estimated cost File98
          $0.95    0.165 DialUnits File110
$0.95     Estimated cost File110

```

```

$2.75    0.509 DialUnits File135
$0.00    1 Type(s) in Format  8
$0.00    1 Types
$2.75    Estimated cost File135
$1.60    0.259 DialUnits File136
$1.60    Estimated cost File136
$1.00    0.333 DialUnits File143
$1.00    Estimated cost File143
$12.05   2.678 DialUnits File144
$1.65    1 Type(s) in Format  3
$0.00    1 Type(s) in Format  8
$1.65    2 Types
$13.70   Estimated cost File144
$17.20   5.059 DialUnits File155
$0.00    1 Type(s) in Format  8
$0.00    1 Types
$17.20   Estimated cost File155
$0.66    0.188 DialUnits File164
$0.66    Estimated cost File164
$2.73    0.244 DialUnits File172
$2.73    Estimated cost File172
$2.85    0.463 DialUnits File185
$2.85    Estimated cost File185
$22.97   1.030 DialUnits File357
$5.20    2 Type(s) in Format  3
$0.00    6 Type(s) in Format  6
$5.20    8 Types
$28.17   Estimated cost File357
$0.74    0.211 DialUnits File369
$0.74    Estimated cost File369
$0.70    0.201 DialUnits File370
$0.70    Estimated cost File370
$0.00    0.329 DialUnits File391
$0.00    Estimated cost File391
$13.79   0.587 DialUnits File434
$13.79   Estimated cost File434
$1.07    0.168 DialUnits File467
$1.07    Estimated cost File467
OneSearch, 29 files, 35.382 DialUnits FileOS
$9.86    TELNET
$348.71  Estimated cost this search
$348.81  Estimated total session cost  35.591 DialUnits

```

Logoff: level 05.10.03 D 10:44:59

You are now logged off